BioSpectrum India February 2021

Tofflon’s mAb Capabilities and Systems

Filling

Buffer preparation/Storage/Distribution

CIP Station Depth filtration

Ultrafiltration concentration
Virus filtration

Chromatography

Bioreactors
Single Use or Stainless Steel
Media preparation /Storage/Distribution

Features:

• Complete SS & Hybrid equipment solution by Tofflon
• Lower operating costs and downtime
• Our design offer high sterility assurance, reduced potential bioburden and
cross contamination
• Increased personnel and product safety
• High standard equipment ensure repetability, reproducbility and robustness of
the process
• Less reliance on personnel interventions and SOP’s
• Fastest delivery and execution of project
• Complies with all regulation for manufacturing, safety & data integrity
• High end automation and integration of all equiment aids reduce personnel
requirement in clean room
• Customization as per requirement of customer to offer flexible designs

Shanghai Tofflon Science and Technology Co.,Ltd.

Address : No.1509, Duhui Road, Shanghai, China 201108

Tel: +86 21 6490 1123

Fax: +86 21 6490 5148

E-mail: [email protected] (sales)

Website: www.tofflon.com

The Open Road to Autonomy

The road to industrial autonomy is open and variable,
offering myriad choices for operational excellence.
Whether your company is at the start of its journey or
well on its way, Yokogawa enables smooth transition from
industrial automation to industrial autonomy — IA2IA.
Key to that transition is OpreX, our evolving suite of
solutions and products comprising control, measurement,
execution, and lifecycle that will help customers optimize
everything from business management to operations.
Yokogawa. Advancing your IA2IA.

yokogawa.com/oprex/

The names of corporations, organizations, products, services and logos herein are either registered
trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

4 BIO CONTENT BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

19 COVER
DESIGN BY:
COVERSTORY DOMINIX STRATEGIC
DESIGN PVT. LTD.
The Indian Biopharma Industry, with
over 300 companies, is growing at

the rate of 15 per cent, which is 3 per
cent more than the previous year’s
12 per cent. This growth was largely
driven by over 20 per cent growth
rate recorded by 8 of the top 20

companies in the biopharma space.
As a result, the Indian Biopharma

Industry has crossed the Rs 25,000
crore mark for the year 2019-20
over the previous year’s figure
of Rs 22,124 crore. In 2017-18 the

industry recorded a revenue of Rs
18,290 crore. The Indian Biopharma

industry, comprising hormones,
insulin, blood products and vaccines

recorded a sales revenue of Rs
25,442 crore for the year 2019-20.

INDIAN BIOPHARMA HITS
RS 25,000 CRORE RIDING 15% GROWTH WAVE

24 25 26 27 28

SERUM INSTITUTE BIOCON LTD NOVO NORDISK BHARAT BIOTECH GLAXOSMITHKLINE
OF INDIA LTD INDIA PVT LTD INTERNATIONAL PHARMACEUTICALS
LTD LTD

ADAR POONAWALLA DR KIRAN VIKRANT SHROTRIYA DR KRISHNA ELLA SRIDHAR VENKATESH
Chief Executive Officer MAZUMDAR-SHAW Managing Director Chairman and Managing Director
Executive Chairperson Managing Director
29 31 33
30 32
SANOFI RELIANCE LIFE INTAS
INDIA LTD BIOLOGICAL E SCIENCES PVT LTD BHARAT SERUMS PHARMACEUTICALS
LTD AND VACCINES LTD LTD

N RAJARAM MAHIMA DATLA KV SUBRAMANIAM SANJIV NAVANGUL BINISH CHUDGAR
Managing Director Managing Director President Chief Executive Officer & Managing Director
Managing Director

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com BIO CONTENT 5

TRENDS TOPVIDEO Vaibhav Tewari,
Co-founder and
17 COO, Portea
Medical, Bengaluru
9 trends of new talks about the
post-COVID era increasing demand
Dr K V BALASUBRAMANIAM, for essential
medical devices at
Life Sciences Consultant and home.
Former Managing Director –
Indian Immunologicals Ltd, Hyderabad

34 34 35

INDIAN PFIZER LTD ZYDUS CADILA
IMMUNOLOGICALS HEALTHCARE LTD
LTD

DR K ANAND KUMAR S SRIDHAR PANKAJ R PATEL Scan the QR Code »
Managing Director Managing Director Chairman
Dr Manjiri Bakre,
35 36 36 Founder & Chief
Executive Officer,
LUPIN LTD MACLEODS ABBOTT INDIA LTD OncoStem
PHARMACEUTICALS Diagnostics,
PVT LTD Bengaluru
points out why
VINITA D GUPTA RAJENDRA AGARWAL ANIL JOSEPH chemotherapy is no
Chief Executive Officer Director Managing Director longer synonymous
with breast cancer.
37 37 38
Scan the QR Code »
SUN PHARMA ELI LILLY & FRESENIUS KABI
INDUSTRIES LTD COMPANY INDIA PVT LTD Dr Debkishore
(INDIA) PVT LTD Gupta,
Consultant, Clinical
DILIP SHANGHVI LUCA VISINI SANJAY GUPTA Microbiologist &
Managing Director Managing Director Managing Director & Head of Infection
Head MU-India Control, CK Birla
Hospital, Kolkata
38 REGULARS shares his thoughts
regarding efficacy of
EMCURE BioEdit ............................................................. 06 COVID-19 vaccines.
PHARMACEUTICALS BioMail ............................................................ 08
LTD Policy and Regulatory News........................ 09 Scan the QR Code »
Company News............................................. 11
SATISH RAMANLAL MEHTA Finance News................................................. 12
Chief Executive Officer & Start Up News................................................ 13
Managing Director World News.................................................... 14
WHO News...................................................... 16
People News................................................... 45
R&D News....................................................... 49
Supplier News................................................ 50

6 BIO EDIT BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

From Nay to Yea

Last month, in this very column, the Central Some have even voiced their doubts about both the
Drugs Standard Control Organisation (CDSCO) vaccines as the approval for the Serum’s Covashield
was praised for deferring the Emergency Use was given on the basis of partial results from studies
Authorisation (EUA) to two anti-COVID-19 vaccines in Britain and Brazil suggesting 70 per cent efficacy.
produced by Indian companies for not providing the Another reason for doubt over both the vaccines is that
requisite data. The CDSCO’s expert committee had no questions were allowed after a statement was read
asked Pune-based Serum Institute, the manufacturer out by the Drug Controller General of India (DCGI)
of Covashield, and Hyderabad-based Bharat Biotech, announcing the emergency use authorisation for both
the manufacturer of Covaxin, to provide more data on the vaccines.
safety and immunogenicity.
The All India Drug Action Network (AIDAN) has
It was also hoped in the column that by the time expressed its shock that in the case of both the approved
readers get to see that editorial in January, it was possible vaccines, there was no information regarding the
that EUA might have been granted and the vaccination specific provisions of the law under which the DCGI
programme would have begun, depending upon how has granted Restricted Emergency Use (REU) approval.
fast the vaccine developers submit the additional data Both the manufacturers have not provided the necessary
that convinces the experts over safety and efficacy of the information regarding the conditionalities attached to
vaccines. the approval. It has asked the regulator to publish all the
data and analyses that form the basis for the approval in
In less than a month’s time, both the vaccines order to verify it independently.
received EUA in January. Alarmingly, Covaxin got
the EUA without submitting the necessary data. The International Association of Bioethics
Understandably, Covaxin’s approval has triggered a emphatically stated that there is no confidence in the
controversy in the country, with experts voicing their way the approvals were done and in a language that
concerns and objections. ‘What made the committee seems to be more creative writing than based on any
rethink their previous dictum and approve the vaccine law. It said that it was important to build confidence in
without Phase III trial efficacy data?’ is a question the regulatory process, the very reason the regulator was
weighing on everyone’s mind. praised in this column earlier and by other media.

Approval granted to Covaxin seems to be contrary to Vaccine scientist Dr Gagandeep Kang was categorical
the regulator’s own guidance of September, 2020 that that no vaccine should be approved without efficacy
50 per cent efficacy would be considered acceptable for data. Thus, approval to Covaxin approved without Phase
EUA as no efficacy data was available and submitted to III trial efficacy data was ‘extremely confusing’.
the regulator. Even the interim data is expected to be
available in a few weeks from now when the EUA has Amidst the controversy, there have been media
already been given. reports of some volunteers in vaccine clinical
trials developing adverse reactions or even dying.
It was informed initially that Covaxin would only be Manufacturers have labelled these incidents as
a “backup.” But that stand too changed in just three days unconnected with the vaccine.
when health officials said it would be given to people
after getting their consent, suggesting both vaccines will By the time the readers will be reading this,
be used. immunisation in India must have been on in full
swing and it could be highly successful also. Yet, the
Several scientists and doctors expressing concerns regulator’s flip-flopping has definitely dented its image
over scant evidence of the vaccine’s efficacy and have as a trustworthy gatekeeper of citizen’s health and well-
also, questioned the approval process. They have said being.
that approving a vaccine without evidence from late
trials is risky and shows a lack of transparency in the Milind Kokje
approval process. Chief Editor

[email protected]



8 BIO MAIL BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

Volume 19 Issue 1 January 2021 www.biospectrumindia.com Total pages including cover 52 Vol 1; Issue 1; January 2021

Glocal2021 setting waves Acknowledgements The coverage on HiMedia in the cover story is
much appreciated. Thank you.
of The cover story has come
out really well in terms - Dipanwita Chakraborty, Mumbai
of featuring the industry
sentiments around the New It’s quite a comprehensive cover story. Cytiva
Year. Congratulations. Merck team congratulates BioSpectrum for compiling
will be happy to support you such great content together.
more actively on topics around
infectious disease, vaccine - Iris Zhao, China
manufacturing, food safety
and high-end technology and Thank you so much for the feature on Infinita
skill building as required by Biotech. It is always a delight to be associated
our country. with BioSpectrum.

- Rekha Bijoy Kumar, - Adarsh Desai, Vadodara
Mumbai

Vol 19; Issue 2; February 2021 MM Activ Sci-Tech Communications

Publisher & Managing Editor: South Region New Delhi INTERNATIONAL
Ravindra Boratkar Alok Srivastava Dr Manbeena Chawla Singapore
Editorial: National Business Head- Executive Editor MM Activ Singapore Pte. Ltd.
Chief Editor: Dr Milind Kokje Ad Sales & Marketing 103-104, Rohit House 3, Saradha Mani
[email protected] “NITON”, Block B, Lower Ground Floor, Tolstoy Marg, Connaught Place, General Manager
Advisor - Content: Vijay Thombre 11/3, Palace Road, Bangalore 560001 New Delhi - 110 001 #08-08, High Street Centre,
Editor: Mobile: +91-9845128747 Mobile: +91-8861043732 1 North Bridge Road,
Narayan Kulkarni Tel.: +91-80-41131912/13 [email protected] Singapore - 179094
[email protected] [email protected] Tel: +65-63369142
Executive Editor: Fax:+65-63369145
Dr Manbeena Chawla Mumbai Pune [email protected]
[email protected] Mr. Nirav Mistry Ankit Kankar USA
Sub Editor: Asst. Manager- Sales Manager BioSpectrum Bureau
Nitesh Pillai 1st Floor, CIDCO Convention Center, Social Media Communications MM Activ Sci-Tech
[email protected] Sector 30A, Vashi, Navi Mumbai, Ashirwad, 36/A/2, S.No. 270, Pallod Communications
Content Team: Maharashtra-400703. Farms, Baner Road, Pune- 411045 Mobile: +91-9579069369
Singapore: Hithaishi C. Bhaskar Mobile - 9586424033 Mobile: +91-9579069369 E-mail: [email protected]
[email protected] [email protected] [email protected] Europe
Social Media Editor: Ankit Kankar Mr. Stuart Smith
[email protected] Nagpur 6 Cobden Court, Wimpole Close,
CFO & Special Correspondent: Manisha Boratkar Bromley, Kent BR2 9JF
Manasee Kurlekar 402, Govind Apartments, Shankar Nagar Square, E-mail: stuart.smith@
[email protected] Nagpur - 440 010. Tel. +91-712-2555 249 globalmediasales.co.uk
Production & Design: E-mail: [email protected]
MM Activ Sci-Tech Communications Printed and published by Tel: +44 (0)20 8464 5577
Anil Walunj Ravindra Boratkar on behalf of MM Activ Sci-Tech Communications Pvt Ltd Mobile: 07973 814753
Product & Marketing Printed at Spectrum Offset, D2/4, Satyam Estate, 1st Floor, Behind
Ankit Kankar C.D.S.S., Erandawane, Pune 411004. Maharashtra. Tel : +91 20 2543 6556 for the accuracy or
[email protected] TIN No: 09565712431 completeness of
Circulation, Subscription and Published from Ashirwad, 36/A/2, S.No. 270, Pallod Farms, information provided
Media Enquiry: Near Bank of Baroda, Baner Road, Pune- 411045.Tel. No: +91 20 2729 1769 therein. Readers must
Asmita Thakar Website: www.biospectrumindia.com undertake research and
[email protected] take professional advice
before acting on any
Disclaimer: Owner of the magazine support these views. information provided in
 Readers are advised to will not be liable for any  Contents and BioSpectrum.
consequences.
make proper enquires  Views expressed in advertisements in
before entering into any the published articles BioSpectrum are purely
commitment in relations are personal opinions for information purposes
to advertisements of the contributors. and the Publisher &
appearing in this BioSpectrum does not Editor of BioSpectrum
publication. The Printer, necessarily claim to give no warranty and
Publisher, Editor and accept no responsibility

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com POLICY AND REGULATORY NEWS 9

Health Ministry releases report on the longitudinal ageing study

Dr Harsh Vardhan, Union with Harvard School of Public on Ageing. It is India’s first and
Minister for Health & Family Health, University of Southern the world’s largest-ever survey
Welfare has released an India California, USA, Dte.GHS, that provides a longitudinal
Report on Longitudinal Ageing United Nations Population Fund database for designing policies
Study of India (LASI) Wave- (UNFPA) and National Institute and programmes for the older
1. LASI is a full–scale national population in the broad domains of
survey of scientific investigation social, health, and economic well-
of the health, economic, and social being. The evidence from LASI
determinants and consequences will be used to further strengthen
of population ageing in India. The and broaden the scope of the
National Programme for Health National Programme for Health
Care of Elderly, Ministry of Health Care of the Elderly and also help in
& Family Welfare has undertaken establishing a range of preventive
the LASI, through International and health care programmes for
Institute for Population Sciences, the older population and most
(IIPS), Mumbai in collaboration vulnerable among them.

Govt launches SARS- India, Suriname ink
CoV-2 genomic
consortium to monitor MoU for cooperation
viral mutations
in health, medicine
The government has launched the Indian SARS-CoV-2
Genomic Consortia (INSACOG), comprising 10 labs namely The Union Cabinet, chaired by Prime
DBT-NIBMG Kalyani, DBT-ILS Bhubaneswar, ICMR- Minister Narendra Modi, has given
NIV Pune, DBT-NCCS Pune, CSIR-CCMB Hyderabad, its approval for the Memorandum of
DBT-CDFD Hyderabad, DBT-InSTEM/ NCBS Bengaluru, Understanding (MoU) between the
NIMHANS Bengaluru, CSIR-IGIB Delhi, and NCDC Delhi. Government of the Republic of India and
The overall aim of the Indian SARS-CoV-2 Genomics the Ministry of Health of the Government
Consortium is to monitor the genomic variations in the of the Republic of Suriname, South America
on cooperation in the field of health and
SARS-CoV-2 on a regular basis medicine. The bilateral MoU will encourage
through a multi-laboratory cooperation between the two countries
network. This vital research through joint initiatives and technology
consortium will also assist in development in the health sector. It will
developing potential vaccines strengthen bilateral ties between India
in the future. The consortium and Suriname. It leads towards achieving
will ascertain the status of new Atmanirbhar Bharat by way of sharing
variant of SARS-CoV-2 (SARS- of expertise in public health system,
CoV-2 VUI 202012/01) in the and by promoting mutual research in
country, establish a sentinel various relevant areas. The main areas of
surveillance for early detection cooperation between the two governments
of genomic variants with public health implication, and include exchange and training of medical
determine the genomic variants in the unusual events/ doctors, officials, other health professionals
trends (super-spreader events, high mortality/morbidity and experts; assistance in development
trend areas etc.). INSACOG will monitor the genomic of human resources and setting up of
variations on a regular basis through the multi-laboratory healthcare facilities; short term training
network. Knowledge generated though this vital research of human resources in health; regulation
consortium will also assist in developing diagnostics and of pharmaceuticals, medical devices and
potential therapeutics and vaccines in the future. cosmetics and exchange of information
thereon; promotion of business development
opportunities in pharmaceuticals.

10 POLICY AND REGULATORY NEWS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

Govt works towards AYUSH AYUSH
export promotion council
Ministry
The Ministry of Commerce and Minister has advised the industry
Industry and the Ministry of leaders to work simultaneously proposes
AYUSH have decided to work on the quality and pricing of
together to set up an Export their products, so that they DIM at AIIMS
Promotion Council to boost become increasingly competitive
AYUSH exports. The government in the global market. Ministry of Ministry of AYUSH and All
is of the view that trade and AYUSH will work in collaboration India Institute of Medical
commerce in the AYUSH sector with Bureau of Indian Standards Sciences (AIIMS) have decided
needs to be up scaled quickly to develop international to initiate work on setting up
in order to meet the growing standards for AYUSH products as a Department of Integrative
demands from India and abroad, well as services. In addition, the Medicine (DIM) at AIIMS.
and to serve the larger number of government will work with the This was decided in a joint visit
people who are now looking up industry to identify best practices and review by Vaidya Rajesh
to these systems for maintaining or success stories and promote Kotecha, Secretary, AYUSH
their health. The Commerce them amongst the public. and Dr Randeep Guleria,
Director, AIIMS of the Centre
India, UK accelerate for Integrative Medicine and
collaboration on vaccines Research (CIMR) at AIIMS,
New Delhi. Considering the
UK Foreign Secretary Dominic Raab met with Indian Prime Minister research work, other activities
Narendra Modi to discuss UK and India working together as a force and accomplishments of
CIMR, it was felt that setting
for good and launching a pioneering new up dedicated OPD and IPD
vaccines hub, which will share best practices beds for CIMR could be the
for regulation and clinical trials, and foster next steps in the growth and
innovation. The new hub will enable British and development of CIMR. Both
Indian experts to share knowledge on clinical Secretary AYUSH and Director
trials and regulatory approvals and get vaccines AIIMS agreed that considering
to people who need them most in a safe, secure the increased interest of
and energy-efficient way. It will protect the UK patients at AIIMS in the
and India by enhancing cooperation on the CIMR and the growing body
development and distribution of coronavirus of research work of the Centre
vaccines, better aligning the international regulation of vaccines and it could be feasible to further
fostering partnerships to develop innovation moonshots that can define develop it into a standalone
vaccine delivery over the next decade and beyond. Department for Integrative
Medicine at AIIMS in the
short-term future. This may
be developed with dedicated
faculty and staff to make it into
a permanent Department at
AIIMS.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COMPANY NEWS 11

Glenmark unveils Serum Institute launches
FDC Type 2 diabetes
drug in India first indigenous

Glenmark Pharmaceuticals has launched a fixed dose pneumococcal vaccine
combination (FDC) of its novel, patent protected and
globally researched Sodium Glucose Co-Transporter Serum Institute of India (SII) has announced the
Inhibitor (SGLT2i) - Remogliflozin Etabonate and launch of India’s first indigenously developed
another widely used DPP4 inhibitor (Dipeptidyl pneumococcal vaccine Pneumosil. It has been
Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed developed through a collaboration spanning
dose combination is indicated for the management over a decade among SII, Programme for
of Type 2 diabetes. The combination will contain Appropriate Technology in Health (PATH)
Remogliflozin (100 mg) + Vildagliptin (50 mg) in a and Bill and Melinda Gates foundation. Driven
fixed dose and must be taken twice daily to improve by the philanthropic commitment of SII to
glycemic control in patients. Glenmark has launched protect every family with affordable vaccines,
the same under two brand names Remo V and Remozen Pneumosil comes with the advantage of presence
V. Glenmark is the first company in the world to launch of stereotypes 6A & 19A. The composition of
Remogliflozin + Vildagliptin fixed dose combination the WHO pre-qualified vaccine is specially
and India is the first country to get access to this FDC tailored as per the prevalence of the top 10
drug. While the average daily cost of therapy of existing serotypes of S. pneumoniae in India and other
brands in the same drug category is Rs 78, Glenmark’s regions of the world, which is the unique feature
Remogliflozin-Vildagiptin combination has been of this conjugate vaccine. The vaccine will
launched at a breakthrough price of Rs 14 per tablet, provide effective and long-lasting protection for
to be taken twice daily; which amounts to Rs 28 as the children against pneumococcal diseases. The
per day cost of therapy. This cost is 65 per cent lower vaccine makes SII the world’s third supplier of
than the other available SGLT2 & DPP4 combination pneumococcal conjugate vaccines (PCV) under
drugs in the market. the pneumococcal Advance Market Commitment
(AMC), and the first developing country vaccine
manufacturer to access the global PCV market.

DCGI approves Zydus Cadila’s Saroglitazar Mg for NAFLD

Zydus Cadila has announced that In March 2020, Saroglitazar Mg had
the Drug Controller General of India received approval for the treatment
(DCGI) has approved its New Drug of NASH. Zydus achieved positive
Application (NDA) for Saroglitazar results in the EVIDENCES III trial
Mg for the treatment of non-alcoholic (CTRI/2015/10/006236), a Phase III
fatty liver disease (NAFLD) in India. liver biopsy trial of Saroglitazar Mg 4 mg
Saroglitazar Mg was launched in versus Placebo in Indian patients with
India in September 2013, for the NASH. The trial evaluated histological
treatment of diabetic dyslipidemia and improvement of NASH using liver biopsy
hypertriglyceridemia in patients with at the end of 52 weeks and successfully
type-2 diabetes not controlled by statins met primary and secondary endpoints.
alone. In January 2020, Saroglitazar Saroglitazar Mg 4 mg demonstrated a
Mg received an approval for the significant reduction in liver fat, liver
treatment of Type 2 Diabetes Mellitus. enzymes and disease activity.

12 FINANCE NEWS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

Piramal Pharma invests $32M to expand API facility in US

Mumbai based Piramal Pharma 8,500 square feet of production for process development and
Limited’s Pharma Solutions space, will provide significant GMP manufacture for clinical
business, a leading contract benefits to customers and trials at scales up to 100L. The
development and manufacturing patients. Capacity will increase expansion is planned to be ready
organization (CDMO), has in large-scale manufacturing for customers beginning Summer
announced plans to expand its with the addition of new reactors 2022. It is expected that the
facility in Michigan in the US capable of handling up to 4000L. expansion will add approximately
with additional capacity and new Piramal Pharma Solutions (PPS) 20 new hires to the site, bringing
capabilities for the development is also adding two new kilo labs the total headcount to more
and manufacturing of Active than 180 employees and further
Pharmaceutical Ingredients benefitting the local economy.
(APIs). The company is investing This would be the seventh major
$32 million in the facility to keep acquisition or expansion by PPS
up with expected demand based in North America in the past six
on current forecasts, including years demonstrating a sustained
potential new opportunities. This substantial commitment to
expansion of more than 25,000 patients, customers, employment,
square feet, which includes and growth.

Advanced Enzymes Biological E receives
$5M funding from CEPI
picks 51% stake in
CEPI, the Coalition for Epidemic Preparedness Innovations,
SciTech Specialities based in Norway, and Biological E, a Hyderabad based
vaccines and pharmaceutical company, have announced a
The board of directors at Thane based collaboration to advance the development and manufacture
Advanced Enzymes Technologies have of Biological E’s COVID-19 subunit vaccine candidate. CEPI
approved the issuance of 4,92,630 equity will initially contribute up to $5 million toward the cost of
shares of SciTech Specialities to be offered scaling up the process for manufacturing the vaccine, and
on a preferential issue or private placement will explore providing additional funding to Biological E
basis. It also includes the purchase of 27,778 with the goal of potentially enabling the production of 100
million doses in 2021. CEPI and Biological E are committed
equity shares to global equitable access of COVID-19 vaccines and have
from selling agreed that vaccine output funded by CEPI’s investment
shareholders will be made available for procurement and allocation,
of SciTech, if proven to be safe and effective, through the COVID-19
aggregating to Vaccine Global Access (COVAX) Facility. The COVAX
5,20,408 equity Facility aims to ensure equitable access to COVID-19
shares i.e. 51 per vaccines for all countries, at all levels of development, that
cent of the equity wish to participate.
share capital.
The total cost of
acquisition is Rs
31.62 crore and the consideration would be
paid in cash. The acquisition is estimated to
be completed by January 31, 2021. SciTech
Specialities is a contract manufacturing
company with niche technology, specialising
in effervescent granules and tablets. It
was formed in 2007 and is focused on
animal health, pharma, and nutraceutical.
It has two manufacturing facilities for
nutraceuticals and pharmaceuticals.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com START UP NEWS 13

JAN-CARE Govt seeks startups’
participation for COVID-19
challenge to vaccine distribution

catalyse health tech Ministry of Health and Family Welfare (MoHFW) along
with Ministry of Electronics and Information Technology
innovation in India (MeitY) have announced the launching of CoWIN, a
grand challenge for strengthening the COVID-19 Vaccine
Biotechnology Industry Research Intelligence Network (CoWIN) system, a digitalised
Assistance Council (BIRAC) and The platform to be used to effectively roll out and scale up the
National Association for Software & mechanism for COVID-19 vaccine distribution system,
Services Companies (NASSCOM) in nationally. To be launched on the MSH (MeitY Start-up
collaboration with Grand Challenges Hub) portal, a collaborative platform developed under
India (GCI) have launched JAN-CARE, the aegis of MeitY towards building meaningful synergies
a nationwide innovation challenge to in the Indian tech startup space, the challenge invites
discover, design and scale the health-tech participation from talented and innovative startups and
innovations, which work in low resource- emerging technology specialists to augment and scale the
settings especially, in rural & semi urban CoWIN platform. The top 5 applicants will be provided
environments. These innovations will be the CoWIN APIs (Application Programming Interface) to
built on technologies such as artificial prove the efficacy of their solutions for possible integration
intelligence (AI), IoT, machine learning, with the platform. Each shortlisted applicant at this stage
big-data and analytics, making use of stands a chance to win Rs 2 lakh covering their logistical
telehealth platforms to enhance the requirements. The solutions once integrated with the
access, quality and affordability of the platform through open APIs will be assessed for robustness
delivery of healthcare at the last mile. This and scalability. Top 2 contestants from the challenge will be
unique challenge will identify upto 25 best rewarded with Rs 40 lakh and 20 lakh respectively.
healthtech solutions from startups/ SMEs
and provide pilot test beds in collaboration
with state governments and industry to help
their validation and scale up for adoption.

Bangalore Bioinnovation Centre
bags innovation leadership award

Bangalore Bioinnovation Centre extraordinary work and track the
(BBC) received the Innovation record of their achievements. The
Leadership Award citation during shortlist is then reviewed by a jury
Karnataka Innovation Leadership comprising of senior professionals
Awards ceremony organised by from across the globe. Those who
World Innovation Congress. The can make a difference to the lives of
Karnataka Innovation Leadership others were chosen. For the quality
Awards are intensely researched of their work, global reach and
process undertaken by the research outlook and ability to contribute
cell. It is the iconic job of the value of social change. Change can
research cell to produce a shortlist be quantified - especially since it
of individuals who are doing impacts the lives of many.

14 WORLD NEWS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

Korea conducts
typhoid vaccine
study in Nepal

Vi-DT typhoid conjugate vaccine, developed jointly

by the International Vaccine Institute (IVI) and SK

Bioscience based in South Korea, has met the primary

endpoints in a Pase III study in Nepal. The primary

endpoints were based on immune non-inferiority with

the World Health Organisation (WHO)-prequalified

typhoid conjugate Sri Lanka formulates

vaccine, Typbar- new mental health policy

TCV, in terms of Cabinet approval has been granted to formulate
a new national policy for mental health in Sri
serconversion rate, Lanka covering 2020 to 2030. The previous
mental health policy in Sri Lanka had been
which confirms the new formulated in 2005. Thereby, the need for
its updation has been recognized for the
candidate TCV induces coordination and supervision of strategic
progress according to the current requirements
an immune response although. A mental health policy formulates the
strategic framework for the prevention of mental
that is not inferior to illnesses, healing, rehabilitation, and mental
health promotion within the community. The
Typbar-TCV. It was a Government of Sri Lanka acknowledges that the
country has high suicide rates and increasing
challenging project to substance misuse and psychosocial problems.
The new policy will aim at strengthening
get the sites in Nepal leadership and research, providing extended
mental health services, human resource
ready. However, development and empowering the community.

with the help of the

authorities in Nepal and other collaborators, the

project team in Nepal could managed to complete this

study within timeline and with quality. A Phase I safety

trial of Vi-DT was first conducted in the Philippines

in volunteers aged 2-45 years and showed that the

vaccine was safe and immunogenic four weeks after

first dose. Following the successful completion of a

Phase II trial with infants under two years, large-scale

Phase III studies with a single-dose of Vi-DT started in

the Philippines and Nepal in 2020.

Pakistan shares COVID-19 vaccination strategy for 2021

The National Command and online National Immunisation
Operation Centre (NCOC) in Management System (NIMS)
Pakistan has announced that all has been developed by the
front line healthcare workers NCOC in collaboration with
(FLHCW) would be inoculated the National Information
with COVID-19 vaccine by Technology Board (NITB),
the first quarter of 2021. As which would serve as a brain
per the strategy, the front of the entire immunisation
line healthcare workers are in process. In addition, vaccine
the first stage of inoculation administration cells would be
process of the vaccine whereas set up at all district and sub-
in the next level, people division headquarters, hospital
above 65 years would be and regional health centres
administered the vaccine due to ensure grass root level
to their higher vulnerability approach of the vaccination
to the deadly virus. A special process.

BIOSPECTRUM | JANUARY 2021 | www.biospectrumindia.com WORLD NEWS 15

USFDA issues EUA to Moderna & Pfizer COVID-19 vaccine

The US Food and Drug and potential benefits outweigh for the vaccine’s use in people 18
Administration (FDA) has issued the known and potential risks years of age and older. The vaccines
emergency use authorization supporting the company’s request contain messenger RNA (mRNA),
(EUA) for the Pfizer-BioNTech which is the genetic material. The
COVID-19 vaccine and the vaccines contain a small piece of
Moderna COVID-19 vaccine to be the SARS-CoV-2 virus’s mRNA
distributed in the US. The FDA has that instructs cells in the body to
determined that both COVID-19 make the virus’s distinctive “spike”
vaccines have met the statutory protein. After a person receives this
criteria for issuance of an EUA. vaccine, their body produces copies
The totality of the available data of the spike protein, which does
provides clear evidence that the not cause disease, but triggers the
two COVID-19 vaccine may be immune system to learn to react
effective in preventing COVID-19. defensively, producing an immune
The data also show that the known response against SARS-CoV-2.

Global partners seek COVAX plans
urgent cooperation to
end paediatric AIDS global rollout of

Global partners that are committed to ending paediatric COVID-19 vaccine
acquired immunodeficiency syndrome (AIDS) have come
together to call on countries to rapidly scale up access starting Q1 2021
to optimal, child-friendly HIV treatment for infants and
children. The partners include the United Nations Children’s COVAX, the global initiative to ensure
Fund, the World Health Organisation (WHO), UNAIDS, the rapid and equitable access to COVID-19
United States President’s Emergency Plan for AIDS Relief, the vaccines for all countries, regardless
Global Fund to Fight of income level, has announced that it
AIDS, Tuberculosis had arrangements in place to access
and Malaria, Unitaid, nearly two billion doses of COVID-19
the Elizabeth Glaser vaccine candidates, on behalf of 190
Paediatric AIDS participating economies. For the vast
Foundation, and majority of these deals, COVAX has
the Clinton Health guaranteed access to a portion of the
Access Initiative first wave of production, followed by
(CHAI). The United volume scales as further supply becomes
States Food and Drug available. The arrangements will enable
Administration (FDA) all participating economies to have
recently gave tentative access to doses in the first half of 2021,
approval for the first with first deliveries anticipated to begin
generic formulation of in the first quarter of 2021, contingent
dolutegravir (DTG) 10 mg dispersible tablets. This approval upon regulatory approvals and countries’
was the result of an innovative partnership between Unitaid, readiness for delivery. Given these are
CHAI and ViiV Healthcare, together with generic suppliers, arrangements for two billion doses of
which accelerated the timeline of development by several vaccine candidates, which are still under
years. This now means that WHO-recommended preferred development, COVAX will continue
first line DTG-based antiretroviral treatment is now available developing its portfolio: this will be
in more affordable and child-friendly generic formulations for critical to achieve its goal of securing
young children and infants as young as four weeks of age and access to two billion doses of safe and
weighing more than 3 kg. effective, approved vaccines that are
suitable for all participants’ contexts,
and available by the end of 2021.

16 WHO NEWS BIOSPECTRUM | JANUARY 2021 | www.biospectrumindia.com

WHO, IFRC Pfizer vaccine first to receive
sign MoU on emergency validation from WHO
emergency
medical services The World Health Organization (WHO) has listed the Comirnaty
COVID-19 mRNA vaccine for emergency use, making the Pfizer/
The World Health Organization BioNTech vaccine the first to receive emergency validation from
(WHO) and the International WHO since the outbreak began a year ago. The WHO’s Emergency
Federation of Red Cross and Red Use Listing (EUL) opens the door for countries to expedite their own
Crescent Societies (IFRC) have regulatory approval processes to import and administer the vaccine.
launched a new collaboration It also enables UNICEF and the Pan-American Health Organization
to strengthen the delivery of to procure the vaccine for distribution to countries in need. The
emergency medical and health Comirnaty vaccine requires storage using an ultra-cold chain as it needs
services during humanitarian to be stored at -60°C to -90°C degrees. This requirement makes the
crises. The MoU, also known as vaccine more challenging to deploy in settings where ultra-cold chain
the Red Channel Agreement, equipment may not be available or reliably accessible. For that reason,
is the culmination of years of WHO is working to support countries in assessing their delivery plans
collaboration between IFRC and and preparing for use where possible.
the WHO Emergency Medical
Team (EMT) Initiative. The WHO announces updates on
new agreement will bring more systematic screening for TB
synergies to health emergency
response between the two World Health Organization using new tools and approaches
international organizations, (WHO) has announced a number to reach all people with care
particularly in technical of updates to its forthcoming could help bridge this gap.
standards, accountability, guidance on the systematic Measures like screening need to
and coordination. It aligns screening of tuberculosis (TB) be stepped up rapidly to reach
the IFRC’s system with that of disease. This will help national the global target of treating at
the WHO Emergency Medical TB programmes, public and least 40 million people with TB
Teams global classification private healthcare providers, by 2022. The updated guidance
system, in doing so recognizing funders and other stakeholders will avail of the latest evidence
the IFRC’s Emergency Response to prepare for the changes that and best available practices on,
Units as EMTs and heightens will be introduced when the amongst others, new approaches
the involvement of IFRC teams new guidelines are released in to screening of people at risk, the
and National Red Cross and early 2021. It is estimated that role of new technologies such as
Red Crescent Societies in the close to three million people computer-aided detection (CAD)
capacity building efforts of the with TB are not diagnosed or to interpret chest radiography
EMT network. reported annually around the and the use of molecular rapid
world. Improved TB screening diagnostics for screening.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com TRENDS 17

trends of new
post-COVID era

As the world wakes up to the new post-COVID «
reality, the vaccine industry is entering a new
paradigm that is one in which vaccines are Dr K V
perceived as effective medical interventions, which
will have wider acceptance in the society, and which Balasubramaniam,
need to be supported.
Life Sciences
The global vaccine industry has hit pay dirt,
thanks to the COVID-19 pandemic! Never has Consultant and
it been so good for the industry.
The scramble to find medical solutions to one Former Managing
of the worst nightmares that haunts humanity has
found a forceful response from the vaccine industry. Director – Indian
We now have vaccines which promise protection
against this horrible pandemic. The world is now Immunologicals Ltd,
more positive about the post pandemic future albeit
with new social norms. Hyderabad

Once perceived to be cheap with production the vaccine industry into a new growth orbit. Just
in the ambit of government institutes, and largely think, even if one half of the world population of 7.6
ignored by the pharmaceutical majors, vaccines are billion gets vaccinated for COVID each year with an
now perceived to be of immense social value and average price settling down to $2 per dose (there
new business growth drivers in the pharmaceutical would of course be wide disparity between prices
industry. in high income and low-income countries) and
accounting for 10 per cent wastage, the market would
The defining changes came about at the beginning be in the region of $16 billion! This is assuming
of this century with the United Nations adopting the that the vaccines develop not just robust protective
Millennium Development Goal (MDG) in 2000 of immunity but also sterilising immunity, which the
reducing child mortality by half by 2015. Impetus to vaccines approved so far have not yet convincingly
this was given by the creation of Global Alliance for proved to be conferring.
Vaccines and Immunization (GAVI) in 2000 to fund
immunization initiatives in low-income countries, Compare this with the size of global vaccine
and more importantly develop low-cost vaccine industry which is estimated to be presently $36
solutions alongside new vaccine technologies. This billion in revenues. That would be a huge jump of 44
apart, new recombinant biotechnology methods per cent of industry revenues with just one product.
were able to address vaccine solutions to pressing
infectious disease needs. On the profitability side, we can see a huge surge
in profitability, considering that the prices garnered
The private sector seized the initiatives and are disproportionately high compared to cost of
blockbuster vaccines soon hit the market. For manufacture, with development costs funded by
example, the pneumococcal vaccine market is now governments and public liability clauses waived. That
worth $8 billion, the human papilloma virus (HPV) would be hitting pay dirt for the vaccine companies!
vaccine is worth $3.8 billion, and the rotavirus We are already witnessing this with valuations of
vaccine is worth $1.6 billion. No longer are vaccines vaccine companies across the world soaring to new
in the ambit of government institutes. No longer are highs.
they perceived as cheap. No longer are they low in the
priority list of pharmaceutical majors. We must note however that the ability of the
vaccine industry to seize the opportunity and make
The COVID-19 pandemic is now poised to propel a response at supersonic speed has not happened
overnight. There have been years and years of
coordinated research in new vaccine technologies
and new manufacturing systems behind this. The
past disease outbreaks of SARS, Ebola, MERS,
Nipah and Zika led the industry think of how it could
respond to new pandemic situations, about how new

18 TRENDS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

There are just about 30 vaccines in use today and diseases like the ones we have witnessed in the
about 26 more in development. An accelerated rate last ten years need a more concerted and effective
of development for the 26 vaccines and for the new response.
emerging zoonotic diseases with new technologies, can
result in a sustained rise in the fortunes of the global 4. Higher levels of venture capital and larger
vaccine industry. capital investments in the industry which focus on
creating larger capacities and flexible manufacturing
technologies would help and how the regulatory systems.
processes can be accelerated for emergency
approvals. It is worth mentioning the role of the 5. Higher outlays by governments for mass
Coalition for Epidemic Preparedness innovations immunizations supported by better political
(CEPI) conceived in 2015 and launched in Jan 2017, championing of the case for vaccine solutions to
which effectively marshalled resources to fight future emerging diseases.
pandemics. The vaccine response to COVID-19 is a
shining example of CEPI’s success. 6. Large private markets for new vaccines from
the society which sees more value in vaccination for
We now have new technology platforms in social good.
the mRNA, viral vectored and synthetic peptide
vaccines working for a COVID-19 vaccine response. 7. A more open regulatory process which looks
This is most definitely a disrupting and trailblazing at reducing the time to market new vaccines being
transformation for the industry. More important, developed from a better understanding of the
questions are being asked about why the regulatory correlates of protection in the clinical studies.
processes should not be reviewed to reduce vaccine
development and deployment time frames from 8-10 8. A growing recognition of the digital overlay
years to just 3-4 years. required for large scale immunization efforts.

Therefore, even as the world wakes up to the 9. The possibility of more public private
new post-COVID reality, the vaccine industry is partnerships to resolve urgent health issues that
entering a new paradigm. The new paradigm is one haunt our society.
in which vaccines are perceived as effective medical
interventions, which will have wider acceptance in There are just about 30 vaccines in use today and
the society, and which need to be supported. The about 26 more in development. An accelerated rate
trends that are visible are: of development for the 26 vaccines and for the new
emerging zoonotic diseases with new technologies,
1. A spate of new vaccines developed using new can result in a sustained rise in the fortunes of the
technologies and even vaccines presently in use, global vaccine industry.
redeveloped with new technologies.
However, considering that the supersonic
2. New initiatives for handling future pandemics response to COVID-19 vaccine development has been
giving fillip to the efforts already made in this due to the huge amount of money poured for vaccine
direction by the multilateral agencies. development, large advance purchase commitments,
creation of heightened sense of urgency and
3. A new realization that emerging zoonotic unconditional waiver of public liability for vaccine
companies, it remains to be seen if similar responses
play out in the future for emerging infectious and
pandemic diseases.

There is a section of leaders in the industry who
call for caution in any assessment of the future till
the dust has settled after the COVID-19 pandemic.
There is also the need to ensure that people in poor
countries are not left behind, about which CEPI
is working to solve with its COVAXX facility. For
countries burdened with the high cost of vaccinating
their populations, the possibility of imposing price
controls or invoking compulsory licensing clauses on
IPR cannot also be ruled out. All this calls for more
responsible behaviour by the vaccine industry.

Notwithstanding this, it can be stated that
there would be significant positive changes which
can propel the industry to new orbits. If any, our
generation will be witness to the unfolding of the
new vaccine paradigm, just as we were witness to the
internet revolution.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 19

INDIAN BIOPHARMA

HITS RS 25,000

CRORE

1 5 %RIDING
GROWTH WAVE
The Indian Biopharma Industry, with over 300
companies, is growing at the rate of 15 per cent, According to All Indian Origin Chemists & Distributors
which is 3 per cent more than the previous year’s (AIOCD) Pharmasofttech AWACS Pvt. Ltd, the overall Indian
12 per cent. This growth was largely driven by domestic biopharma market registered a 10 per cent growth
over 20 per cent growth rate recorded by 8 of the with the vaccine market (out of pocket) witnessing a growth
top 20 companies in the biopharma space. As a result, the of 7 per cent, the insulin market 8 per cent, blood products
Indian Biopharma Industry has crossed the Rs 25,000 crore 15 per cent and hormones market at 11 per cent. There
mark for the year 2019-20 over the previous year’s figure of are over 200 companies in blood related products. Zydus
Rs 22,124 crore. In 2017-18 the industry recorded a revenue of Cadila – Biologics is leading the market in the country with
Rs 18,290 crore. The Indian Biopharma industry, comprising sales of Rs 149 crore in 2019-20. Macleods Pharmaceuticals
hormones, insulin, blood products and vaccines recorded a is leading the hormones market in India with Rs 388 crore
sales revenue of Rs 25,442 crore for the year 2019-20. in 2019-20. In the hormones space, too, there are about 200
companies in the business.
The Serum Institute of India Ltd continues to lead
the Indian biopharmaceutical space with a revenue of Rs Only in the insulin and vaccines space the number
5,014 crore followed closely by Biocon with Rs 4,487 crore of companies are less than 20 and 30 respectively.
and Novo Nordisk with Rs 1,465 crore. Top 3 biopharma GlaxoSmithKline Pharmaceuticals continues to lead the
companies contribute to 43 per cent of the total biopharma vaccines business in the country (out of pocket) with sales of
industry of Rs 25,442 crore. And, Top 20 biopharma Rs 714 crore. Novo Nordisk India continues to lead the insulin
companies contribute to 86 per cent of the total biopharma market with Rs 1464 crore. In all these biological segments,
industry. multinational companies are leading the domestic market.
While Indian companies do have some presence, they need
The Western region continues to dominate the to do a lot of heavy lifting to catch up to the multinational
biopharma industry with a contribution of 54 per cent companies.
followed, by the Southern region’s 37 per cent and 3 per cent
coming from the Northern region. The top 10 companies in the human vaccine domestic
market in India (excluding exports) include GlaxoSmithKline,
Though India is a leading vaccine manufacturer, Sanofi, Serum Institute of India, Bharat Biotech, Indian
companies still imported Rs 2,804 crore worth vaccines in Immunologicals, Pfizer, Biological E, MSD (Merck), Panacea
2019-20, as against Rs 2,135 crore worth vaccines imported Biotech and Zydus Cadila. The top 10 companies in the
the previous year. In 2019-20, India imported Rs 1,328 crore animal vaccine domestic market (excluding exports) include
worth insulin products, as against 1,090 crore the previous Indian Immunologicals, Venkateshwara Hatcheries, Brilliant
year. However, vaccines worth Rs 5,723 crore were exported Biopharma, Hester Biopharma, Biovet, MSD, Globion,
in 2019-20 as against Rs 4,453 crore exported in 2018-19. Indovax, Zoetis and Virbac.

20 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

SERUM INSTITUTE
OF INDIA LTD

LEADS THE INDIAN
BIOPHARMACEUTICAL
INDUSTRY WITH

No1 POSITION

Serum Institute of India Ltd continues to lead the Indian
biopharmaceutical industry with revenue of Rs 5014 crore followed
by Biocon (Rs 4487 crore) and Novo Nordisk with Rs 1465 crore.

BioSpectrum Top 20 BioPharma Companies 2020

S Company Revenue Revenue % Category Location Region
No in 2019-20 in 2018-19 Growth
Pune West
1 Serum Institute of India Ltd 5014 4984 1 India Bengaluru South
Bengaluru South
2 Biocon Ltd 4487 3946 14 India Hyderabad South
West
3 Novo Nordisk India Pvt Ltd 1465 1352 8 Mnc Mumbai West
Mumbai South
4 Bharat Biotech International Ltd 1066 782 36 India Telangana West
Mumbai West
5 Glaxosmithkline Pharmaceuticals Ltd 1065 972 10 MNC Mumbai West
Ahmedabad South
6 Sanofi India Ltd 1052 952 11 MNC Hyderabad West
Mumbai West
7 Biological E Ltd 1040 953 9 India Ahmedabad West
Mumbai West
8 Reliance Life Science Pvt Ltd 1018 850 20 India Mumbai West
Mumbai West
9 Bharat Serums & Vaccines Ltd 917 600 53 India Mumbai North
Gurugram West
10 Intas Pharmaceuticals Ltd 850 708 20 India
Pune West
11 Indian Immunologicals Ltd 820 538 52 India
Pune
12 Pfizer Ltd 519 511 2 MNC

13 Zydus Cadila Healthcare Ltd 513 386 33 India

14 Lupin Ltd 478 400 19 India

15 Macleods Pharmaceuticals Pvt Ltd 471 406 16 India

16 Abbott India Ltd 395 371 6 MNC

17 Sun Pharma Laboratories Ltd 193 172 12 India

18 Eli Lilly and Company (India) Pvt Ltd 183 161 14 MNC

19 Fresenius Kabi India Pvt Ltd 182 145 26 MNC

20 Emcure Pharmaceuticals Ltd/ 173 141 22 India
Gennova Biopharmaceuticals Ltd

Top 3 biopharma Top 10 biopharma Top 20 biopharma
companies contribute companies contribute companies contribute

43%to of the total 71%to of the total 86%to of the total

biopharma industry biopharma industry biopharma industry

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 21

BioSpectrum Top 21-50 BioPharma Companies 2020

Sr. No. Company Revenue in 2019-20 Revenue in 2018-19 % Growth Category Location Region
21 Abbott Healthcare Pvt Ltd 157 129 22 MNC Mumbai West
22 Panacea Biotec Ltd 140 218 -36 India New Delhi North
23 Haffkine Bio-Pharmaceutical Corporation Ltd 126 85 48 India Mumbai West
24 Brilliant Bio Pharma Pvt Ltd 125 130 -4 India Hyderabad South
25 Hester Biosciences Ltd 120 128 -6 India Ahmedabad West
26 La Renon Healthcare Pvt Ltd 92 71 30 India Ahmedabad West
27 MSD Pharmaceuticals Pvt Ltd 85 96 -12 MNC Mumbai West
28 Dr. Reddys Laboratories Ltd 79 119 -34 India Hyderabad South
29 Globion India Pvt Ltd 71 56 27 India Coimbatore South
30 Indovax Pvt Ltd 70 51 36 India Gurugram North
31 Bharat Immunologicals and Biologicals Corporation Ltd 67 84 -20 India Bulandshahr North
32 Zoetis India Ltd 61 MNC Mumbai West
33 Micro Labs Ltd 60 42 43 India Bengaluru South
34 Mankind Pharmaceuticals Ltd 58 52 12 India New delhi North
35 Ranbaxy Laboratories Ltd 57 56 1 India New Delhi North
36 Zuventus Healthcare Ltd 56 57 -1 India Mumbai West
37 Cipla Ltd 49 32 57 India Mumbai West
38 Paviour Pharmaceuticals Pvt Ltd 44 33 32 India New Delhi North
39 Samarth Life Sciences Pvt Ltd 43 35 25 India Mumbai West
40 Shreya Life Sciences Pvt Ltd 36 34 7 India Mumbai West
41 RPG Life Sciences Ltd 30 22 38 India Mumbai West
42 Wallace Pharmaceuticals Ltd 29 24 22 India West
43 Ozone Pharmaceuticals Ltd 27 33 -17 India Goa North
44 Alkem Laboratories Ltd 25 23 8 India New Delhi West
45 Juggat Pharma Ltd 24 23 5 India Mumbai South
46 Ferring Pharmaceuticals Pvt Ltd 23 19 19 MNC West
46 Boehringer Ingelheim India Pvt Ltd 23 18 24 MNC Mysuru West
47 Astrazeneca Pharma India Ltd 21 21 0 MNC Mumbai South
48 Jagsonpal Pharmaceuticals Ltd 19 20 -5 India Mumbai North
48 Corona Remedies Pvt Ltd 19 20 -6 India Bengaluru West
48 Neon Laboratories Ltd 19 18 5 India New Delhi West
49 Claris Lifesciences Ltd 18 25 -26 India Ahmedabad West
49 Mercury Health Care Pvt Ltd 18 17 8 India Mumbai West
50 Cadila Pharmaceuticals Ltd 17 21 -16 India Ahmedabad West
50 Oaknet Healthcare Pvt Ltd 17 16 7 India Mumbai South
50 Raptakos, Brett & Co. Ltd 17 16 7 India Ahmedabad West
Bengaluru
Mumbai

BIOSPECTRUM BIOPHARMA
SURVEY AND METHODOLOGY

BioSpectrum India, a 2020. In this survey we looked capture the needed information
leading B2B media at only the Biopharma Industry for the analysis. This was done
platform in Lifesciences with companies specializing in during October 2020 to December
space since 2003 Biologics/ Recombinant products/ 2020 (Sales revenues of all the
has re-launched its mAbs/ Vaccines/ Insulin. We companies are in Rs Crore and
ranking special edition in June highlighted the companies (both Rs 70= 1USD). Companies shared
2019 after gap of 2 years. We have MNCs and domestic players) based information with us to the extent
delayed this survey and ranking on their achievements in the past it was possible by them. We have
exercise in 2020 due to COVID-19, financial years. collected information about listed
as companies were given companies from stock exchange,
extended period to submit their A detailed questionnaire financial agencies and speaking
financial returns to December (survey form) was sent to over 100 with industry experts as well.
companies in biologicals space to

#The revenues considered for the analysis are biologicals sales and service figures. In several cases, where revenue figures were not available,
estimates were arrived in discussion with industry experts.
#For all the ranking purposes, we have taken the biopharma business only into consideration. Wherever ‘Revenue is mentioned, it means, sales
turnover from biopharma division. Therefore, revenue wherever mentioned is not necessarily the total sales turnover of the company.

22 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

BioSpectrum Top 10 Indian Biopharma companies

Sr. Company Revenue Revenue % Location Region
No. in 2019-20 in 2018-19 Growth
Pune West
1 Serum Institute of India Ltd 5014 4984 1 Bengaluru South
4487 3946 14 Hyderabad South
2 Biocon Ltd 1066 782 36 Telangana South
1040 953 9 Mumbai West
3 Bharat Biotech International Ltd 1018 850 20 Mumbai West
917 600 53 Ahmedabad West
4 Biological E Ltd 850 708 20 Hyderabad South
820 538 52 Ahmedabad West
5 Reliance Life Science Pvt Ltd 513 386 33 Mumbai West
478 400 19
6 Bharat Serums & Vaccines Ltd

7 Intas Pharmaceuticals Ltd

8 Indian Immunologicals Ltd

9 Zydus Cadila Healthcare Ltd

10 Lupin Ltd

BioSpectrum Top 10 MNC Biopharma companies

Sr. Company Revenue Revenue in % Location Region
No. in 2019-20 2018-19 Growth
Bengaluru South
1 Novo Nordisk India Pvt Ltd 1465 1352 8 Mumbai West
1065 972 10 Mumbai West
2 Glaxosmithkline Pharmaceuticals Ltd 1052 952 11 Mumbai West
519 511 2 Mumbai West
3 Sanofi India Ltd 395 371 6 Gurugram North
183 161 14 West
4 Pfizer Ltd 182 145 26 Pune West
157 129 22 Mumbai West
5 Abbott India Ltd 85 96 -12 Mumbai West
Mumbai
6 Eli Lilly and Company (India) Pvt Ltd

7 Fresenius Kabi India Pvt Ltd

8 Abbott Healthcare Pvt Ltd

9 MSD Pharmaceuticals Pvt Ltd

10 Zoetis India Ltd 61

78%Indian companies contribute of the total biopharma

22%industry while remaining by the MNC firms

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com BIOPHARMA / PHARMA 23

BioSpectrum Top 10 Biopharma companies in West

Sr. Company Revenue Revenue % Category Location Region
No. in 2018-19 in 2017-18 Growth
West
1 Serum Institute of India Ltd 5014 4984 1 India Pune
West
2 Glaxosmithkline Pharmaceuticals Ltd 1065 972 10 Mnc Mumbai West
West
3 Sanofi India Ltd 1052 952 11 Mnc Mumbai West
West
4 Reliance Life Science Pvt Ltd 1018 850 20 India Mumbai West
West
5 Bharat Serums & Vaccines Ltd 917 600 53 India Mumbai West
West
6 Intas Pharmaceuticals Ltd 850 708 20 India Ahmedabad

7 Pfizer Ltd 519 511 2 Mnc Mumbai

8 Zydus Cadila Healthcare Ltd 513 386 33 India Ahmedabad

9 Lupin Ltd 477 400 19 India Mumbai

10 Macleods Pharmaceuticals Pvt Ltd 471 406 16 India Mumbai

BioSpectrum Top 10 Biopharma companies in South

Sr. Company Revenue Revenue % Category Location Region
No. in 2018-19 in 2017-18 Growth
Bengaluru South
1 Biocon Ltd 4487 3946 14 India
Bengaluru South
2 Novo Nordisk India Pvt Ltd 1465 1352 8 MNC Hyderabad South
Telangana South
3 Bharat Biotech International Ltd 1066 782 36 India Hyderabad South
4 Biological E Ltd 1040 953 9 India Hyderabad South
5 Indian Immunologicals Ltd 820 538 52 India Hyderabad South
6 Brilliant Bio Pharma Pvt Ltd 125 130 -4 India Coimbatore South
7 Dr. Reddys Laboratories Ltd 119 -34 India Bengaluru South
8 Globion India Pvt Ltd 79 56 27 India South
9 Micro Labs Ltd 71 42 43 India Mysuru
10 Juggat Pharma Ltd 60 23 5 India
24

BioSpectrum Top 10 Biopharma companies in North

Sr. Company Revenue Revenue % Category Location Region
No. in 2018-19 in 2017-18 Growth
North
1 Eli Lilly and Company (India) Pvt Ltd 183 161 14 Mnc Gurugram North
North
2 Panacea Biotec Ltd 140 218 -36 India New Delhi
North
3 Indovax Pvt Ltd 70 51 36 India Gurugram
North
4 Bharat Immunologicals and 67 84 -20 India Bulandshahr North
Biologicals Corporation Ltd North
North
5 Mankind Pharmaceuticals Ltd 58 52 12 India New Delhi North
North
6 Ranbaxy Laboratories Ltd 57 56 1 India New Delhi

7 Paviour Pharmaceuticals Pvt Ltd 44 33 32 India New Delhi

8 Ozone Pharmaceuticals Ltd 27 33 -17 India New Delhi

9 Jagsonpal Pharmaceuticals Ltd 19 20 -5 India New Delhi

10 Systopic Laboratories Ltd-MEM 12 11 9 India New Delhi

Western region continues to dominate the biopharma industry with contribution of
54% followed by Southern region with 37% and 3% coming from Northern region

24 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | WWW.BIOSPECTRUMINDIA.COM

01 SERUM INSTITUTE OF INDIA LTD

REVENUE MAKING
STRONG INVESTMENTS
₹5014 crore
Pune based vaccine manufacturer Serum Institute of India
DR. CYRUS S. POONAWALLA (SII) recorded a revenue of Rs 5014 crore during the FY19-20
exhibiting a slight growth from the last fiscal’s revenue at Rs
Chairman and Managing Director 4984 crore.
The beginning of the FY19-20 saw the company entering
ADAR POONAWALLA into a research and commercialization collaboration with US based
Dyadic International to develop and manufacture up to twelve
Chief Executive Officer antibodies and vaccines using Dyadic’s C1 gene expression platform.
The FY19-20 also witnessed a remarkable investment of Rs 3000
crore by the company into a new multifunctional production facility
for vaccines. Spread across 2 million square feet, the expansive
new facility will cater to 150 countries across the European and
American continents, increasing SII’s market share to 10-15 per cent
internationally. The new facility, with a production capacity of half a
billion doses manufactured annually, will also help in creating 3000
jobs in the next 5 years.
The later part of the year also saw the company financing a ground-
breaking initiative by the Maharashtra government in collaboration with
Zipline to use a logistics network of autonomous delivery drones to help
transform emergency medicine and critical care within the state.
In addition, during the FY19-20, the company’s pneumococcal
vaccine Pneumosil achieved prequalification status from the World
Health Organisation (WHO). Developed though a collaboration
spanning over a decade between Serum Institute and PATH and
with funding from the Bill & Melinda Gates Foundation, the vaccine
has been recently launched in the market. The FY19-20 also saw the
company unveiling a new variant of its WHO prequalified rotavirus
vaccine called Rotasiil – Liquid to prevent diarrhea.
Another significant collaboration, was announced during the end
of the FY19-20, with US based Aragen Bioscience, a subsidiary of GVK
BIO for the development of multiple stable cell lines to support SII’s
HIV programme.
Founded in 1966, SII supplies around 30 different products
overseas majorly in the categories of bacterial vaccines, polysaccharide
conjugate vaccines, influenza vaccines, anti-sera, viral vaccines, uro-
oncology, recombinant products and combination vaccines. On the
other hand, around 60 products are supplied by the company in India
under bacterial, viral, combination vaccines, recombinant products,
gonadotrophins, and pharma products.
SII manufactures highly specialized lifesaving biologicals like
vaccines using cutting edge genetic and cell based technologies,
antisera and other medical specialties. The company is considered
the world’s largest vaccine manufacturer by the number of doses
produced and sold globally (more than 1.3 billion doses), which
includes polio vaccine as well as diphtheria, tetanus, pertussis, Hib,
BCG, r-hepatitis B, measles, mumps and Rubella vaccines.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 25

02 BIOCON LTD

REVENUE REPORTING
ROBUST GROWTH
₹4487 crore
Bengaluru based biopharmaceutical company Biocon
DR KIRAN recorded a revenue of Rs 4487 crore during the FY19-20 in
MAZUMDAR-SHAW the biopharma space, showing an approximate growth of 14
per cent from the previous financial year where the revenue
Executive Chairperson count was Rs 3946 crore.
The company reported a robust 15 per cent growth in consolidated
revenue at Rs 6529 crore where the small molecules and research
services businesses crossed annual revenue milestones of Rs 2000
crore each, growing by 18 per cent and 10 per cent respectively. The
generic formulations business in the US was the main driver of this
growth backed by consistent client acquisitions and increased market
share for the key active pharmaceutical ingredient (APIs). In order to
further increase its global scale in the manufacturing of fermentation
products, Biocon commenced construction on a greenfield,
fermentation-based manufacturing facility in Visakhapatnam in the
FY19-20. The company is investing Rs 600 crore in this facility.
The FY19-20 also saw the company entering China through a
license and supply agreement with China Medical System Holding.
The company plans to grow its geographic footprint and has identified
10-15 key emerging and developed markets where it will establish a
presence either directly or through a business partner.
On the other hand, the biologics segment reported annual growth
of 29 per cent with revenue at Rs 1951 crore despite a weak fourth
quarter. A key development for the biologics business in the FY19-20
was the investment of $75 million against a 2.44 per cent equity stake
by Activ Pine LLP, an affiliate of the True North Fund in Bengaluru.
This unlocking of value enables Biocon to fund capex investments to
further strengthen its business.
The revenue from the branded formulations business declined 18
per cent to end the year at Rs 536 crore. The business faced pricing
pressures in both its markets, India and UAE. In its novel biologics
portfolio, the company progressed the phase I trial for its novel first-in-
class oral insulin molecule Tregopil.
In addition, Biocon announced the appointment of Siddharth
Mittal as the Chief Executive Officer & Joint Managing Director of
the company starting December 1, 2019. Mittal had been serving as
Biocon’s Chief Financial Officer (CFO) since August 2014.
Founded in 1978, Biocon has created a rich pipeline of novel and
biosimilar assets over the years primarily in the areas of oncology,
diabetes, immunology and autoimmunity. With more than 9000
employees Biocon has today emerged as the largest insulin producer
in Asia. It is also among the top 3 biosimilars players globally in both
rh-Insulin and Insulin Glargine in terms of volume market share.

26 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | WWW.BIOSPECTRUMINDIA.COM

03 NOVO NORDISK INDIA PVT LTD

REVENUE UPGRADING
TO NEXT LEVEL
₹1465 crore
The Indian arm of Denmark headquartered company Novo
VIKRANT SHROTRIYA Nordisk, based in Bengaluru, saw a revenue generation of
Rs 1465 crore in the financial year 2019-20 in the biopharma
Managing Director space, as compared to Rs 1352 crore in the FY18-19, exhibiting
a growth of approximately 8 per cent.
The FY19-20 saw the appointment of Vikrant Shrotriya as the
Managing Director & Corporate Vice President for the India business.
Shrotriya returned to India after 13 years with an overall distinguished
career spanning over 20 years in the healthcare industry, in India and
internationally.

On the diabetes front, Novo Nordisk Education Foundation (NNEF)
and Novo Nordisk India launched a ‘1000-day Challenge’ programme
in November 2018 in New Delhi, along with leading healthcare
practitioners to address uncontrolled diabetes in India. In addition,
for the first time, real-time data on the state of diabetes care was
announced to be made available through an innovative India Diabetes
Care Index. As a follow up, NNEF unveiled the first-year report of the
Impact India: 1000-Day Challenge programme on November 14, 2019
i.e. world diabetes day.

The report revealed that certain cities have shown a dip in the
HbA1c levels. Visakhapatnam in South India, Kolkata in the Eastern
region, Varanasi in the North zone and Pune in the Western region
are the top cities which have shown a decrease in HbA1c levels. To
maximise reach in a diverse country like India, the NNEF is exploring
the possibility of customized or regional forums and will continue to
leverage occasions such as world diabetes day, insulin appreciation
day, etc.

Although Novo Nordisk insulins have been present in India from
1935 marking more than 80 years of uninterrupted supply, the India
arm started operations in 1992 with its headquarters in Bengaluru. The
company has over 1,300 employees, and it is the 5th largest and one of
the fastest growing pharmaceutical MNCs in India.

While the company has a full portfolio of products under its
promise of “an insulin for every Indian” at all stages of therapy, Novo
Nordisk believes that there is a high potential to upgrade its patients
to the next level of therapies and newer insulins, which are available
in the market. The company is also seeing a high potential for incretin
or GLP-1 therapy in India. There are several products in the pipeline,
which should see access in the Indian market in the days to come.

For Novo Nordisk, India is one of the key countries where the
company has applied for advance pricing agreements (APAs) to create
certainty regarding tax payments. Novo Nordisk has APAs in place
covering intercompany transactions with the US, Canada, Japan, India
and China corresponding to more than 60 per cent of total sales.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 27

04 BHARAT BIOTECH
INTERNATIONAL LTD
REVENUE
RELENTLESSLY
₹1066 crore INNOVATING

DR KRISHNA ELLA Arevenue generation of Rs 1066 crore has been recorded for
Hyderabad based Bharat Biotech (BB) in the biopharma
Chairman and Managing Director space for FY19-20. This marks a 36 per cent growth for the
company in comparison to the revenue generation a year
before which was summed up at Rs 782 crore.
The beginning of the FY19-20 saw Hilleman Laboratories entering
into a collaboration with Bharat Biotech for further development,
manufacturing and commercialization of its next-generation
oral cholera vaccine, Hillchol. BB is working towards scaling the
manufacturing process of the vaccine to commercial stage and
establish product specifications required for WHO pre-qualification.

A major achievement for the company took place in December
2019, when BB announced the commercial roll-out of ROTAVAC
5D-lowest dose volume rotavirus vaccine in the world. It is safe and
effective in the prevention of rotavirus diarrhea. ROTAVAC 5D can be
stored at 2-8 degrees, and administered in 5 drops. It is available in
single-dose, multi-dose vials and pre-filled syringes. The company
received commercial licensure and the vaccine is available for sale.

The launch of ROTAVAC 5D was in sync with the company hitting
the landmark figure of 100 million doses supply of Rotavac in 2019. BB
had invested approximately Rs 2 crore to develop new manufacturing
facilities and supporting infrastructure in its Genome Valley plant in
Hyderabad, with an installed manufacturing capacity of 200 million
doses/year. The project was supported in part by the Bill & Melinda
Gates Foundation.

The FY19-20 also witnessed the launch of Chirorab vaccine, earlier
marketed under the trade name Rabipur. It is an inactivated vaccine
used for active pre and post exposure immunisation against rabies.
The launch was announced by Chiron Behring Vaccines that was
acquired by Bharat Biotech from GSK in March 2019 and commercial
operations were restarted in May 2019.

Relentless innovation at Bharat Biotech has made it the first Indian
company to develop successful vaccine candidates against rotavirus,
typhoid, zika, and chikungunya infections through its own dynamic
R&D. The company’s landmark products, Typbar TCV and ROTAVAC,
have been WHO pre-qualified and well-received globally and are
being extensively used in improving global public health. Typbar TCV
is the first clinically proven typhoid conjugate vaccine in the world. It
became the first new vaccine from India to be recommended by the
WHO for routine immunization of children globally against typhoid
fever.

28 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | WWW.BIOSPECTRUMINDIA.COM

05 GLAXOSMITHKLINE
PHARMACEUTICALS LTD
REVENUE
FOCUSING ON
₹1065 crore VACCINES BUSINESS

SRIDHAR VENKATESH For the FY19-20, revenue generation of the Indian arm of
London headquartered GlaxoSmithKline (GSK) in the
Managing Director biopharma space was recorded at Rs 1065 crore, marking a
growth of 10 per cent in comparison to Rs 972 crore generated
in the FY18-19. For GSK Pharmaceuticals, 83 per cent of its
revenue comes from the pharmaceutical space while 17 per cent is
contributed by the vaccines business.
During the FY19-20, Mumbai based GSK Pharma announced
a collaboration with the Regional Centre for Biotechnology (RCB),
an academic institution of national importance established by the
Department of Biotechnology (DBT) to develop doctoral programmes
(PhDs) in the fields of biostatistics and bioinformatics.
Under this initiative, RCB is developing the programme content,
managing logistics and overseeing the running of the full-time
programmes while GSK is investing approximately Rs 5 crore and
ensuring that all course content is shaped to address current industry
needs and opportunities.
The year 2019 also saw the launch of Menveo, a conjugated
meningococcal vaccine indicated for active immunisation of children
from 2 years of age, adolescents and adults to prevent invasive
meningococcal disease caused by Neisseria Meningitidis groups A, C,
W-135 and Y. While Menveo was launched in India in December 2019, it
comes with global experience of 10 years. It is licensed in more than 60
countries.
During the FY19-20, Central Drugs Standard Control Organisation
(CDSCO) approved a new vaccine to help protect children against
typhoid fever. This had first been developed by the GSK Vaccines
Institute for Global Health (GVGH) and then transferred in 2013 to
Hyderabad based Biological E, once proof-of-concept had been
demonstrated. This is the first licensing of a vaccine created in the
GVGH’s labs and successfully further developed and brought to
market through an effective partnership.
Another key highlight of the FY19-20 was the stepping down of
Annaswamy Vaidheesh as the Managing Director. The position is now
held by Sridhar Venkatesh, a senior business leader with more than 24
years of diverse experience in pharmaceuticals and healthcare and has
a strong track record of success in multiple roles within GSK.
On the global front, the final phase IIb results of the company’s
tuberculosis (TB) candidate vaccine, developed in partnership with
International AIDS Vaccine Initiative (IAVI), confirmed primary findings
that the vaccine candidate showed reduced risk of developing
pulmonary TB by half in HIV-negative adults with latent TB infection.
In January 2020, GSK announced the licensing of this asset to the Bill &
Melinda Gates Medical Research Institute.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 29

06 SANOFI INDIA LTD

REVENUE BUILDING
DIGITAL PLATFORMS
₹1052 crore
The Indian arm of the French multinational pharmaceutical
N RAJARAM company headquartered in Paris, Sanofi India saw a revenue
generation of Rs 1052 crore in the FY19-20 in the biopharma
Managing Director space, as compared to Rs 952 crore in the previous year,
exhibiting a growth of approximately 11 per cent.
The insulin portfolio of the company continued to grow strong
double digits in 2019. Lantus, the flagship brand, is ranked among the
top 5 brands in the Indian pharmaceuticals market. The Lantus range
touched the lives of more than 6.7 lakh patients in the year 2019 and
grew by 15 per cent in value strengthening its position as the leading
analog Insulin. Toujeo, which was launched in 2018, further augmented
the current insulin portfolio, offering an advanced standard of care. To
further build awareness on insulins to general public and caregivers of
diabetes patients, a corporate social responsibility (CSR) programme
called as INTOLIFE was launched in 2019.

The oral anti-diabetic drug portfolio continued to grow in volumes
led by Amaryl. In 2019, Amaryl group grew 9 per cent in value despite
significant price cuts on few line extensions. The FY19-20 also saw
the Board of Directors approve a transaction for the slump sale and
transfer of the manufacturing facility of the company at Ankleshwar,
Gujarat to Zentiva for a consideration of Rs 261.7 crore. The Ankleshwar
site is Sanofi India’s oldest manufacturing facility where brands
like Combiflam, Allegra and Amaryl are made. Established in 1987,
the site has a chemistry & biotechnology development centre, and
manufactures more than 6 billion tablets annually.

On the vaccine front, phase III trials started for the hexavalent
pediatric candidate Shan6. It is a cost effective, all-in-one hexavalent
combination vaccine being developed for the Indian market and other
low and middle income countries.

The company continues to build leading edge digital platforms
across all activities. These include digitization of supply chain and
distribution processes, new business intelligence systems and
analytics to support medical and promotion activities. In addition, the
company launched innovative digital campaigns across many brands
covering insulins, allergy and Pain relief during the FY19-20.

In 2019, the company focused on therapy shaping and data
generation initiatives to support physicians in their practice in addition
to generating evidence covering Indian patients. The Safe and Smart
3D and INSUVATION programmes were cascaded by experts to many
physicians across India. In addition, Sanofi also launched Saath7
Connect, an app-based programme with tele-counseling for newly
insulinised patients.

30 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | WWW.BIOSPECTRUMINDIA.COM

07 BIOLOGICAL E LTD

REVENUE INCHING FORWARD

₹1040 crore For the FY19-20, Hyderabad based Biological E (BE) showed a
revenue generation of Rs 1040 crore as compared to Rs 953
MAHIMA DATLA crore in the previous fiscal, displaying an approximate growth
of 10 per cent in the biopharma space.
Managing Director The FY19-20 saw the company open its plant at Genome
Valley in Hyderabad with an investment of Rs 300 crore. Now ready for
commercial production, on about 29 acres of land, this plant would
generate employment opportunities for around 1000 people. This new
facility will help the company’s existing vaccines plant enhance the
production and manufacture new products, which are in the pipeline.
Around the same time, BE received the authorisation from the
health regulatory authorities of India to license and market a new
typhoid conjugate vaccine (TCV). It is an injectable single-dose vaccine
to be administered to children from 6 months old as well as adults and
it contains Vi Polysaccharide derived from C. Freundii conjugated to
CRM197 protein. This vaccine was developed in partnership with the
GSK Vaccines Institute for Global Health, based in Siena (Italy), which
first developed the asset and transferred it to BE in 2013.
In addition, the FY19-20 saw GVK BIO and BE Pharmaceuticals, a
subsidiary of Biological E that focuses on speciality generic injectables
announce a strategic collaboration in drug product development. As
part of the partnership, GVK BIO will develop certain set of injectable
products for BE. The development work will include pre-formulation
studies, formulation development, Analytical method development
and technology transfer to a BE facility.
BE started its journey in vaccine manufacturing in the year
1962 and became the first Indian private company to enter into the
vaccines business. The company has modern manufacturing facilities
that are well equipped for sterile manufacturing of quality products. Its
manufacturing facilities have been inspected by multiple regulatory
agencies.
BE has seven WHO pre-qualified vaccines and is working to
expand its pipeline of generic vaccines. Additionally, it is leveraging
its past experience in the vaccines space to transition to developing
novel vaccines. BE is the largest producer of tetanus vaccine in the
world and leading supplier of pentavalent vaccine. It is also one of the
leading suppliers of Polyvalent Snake Antivenom in India.
BE is one of the leading vaccine companies in India and partners
with global healthcare agencies, including the WHO, UNICEF and
Pan American Health Organisation in their efforts to make life saving
vaccines accessible globally. BE supplies its vaccines to more than 100
countries and has supplied more than 2 billion doses of vaccines in the
last decade alone.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 31

08 RELIANCE LIFE SCIENCES PVT LTD

REVENUE DEVELOPING
NEW OPPORTUNITIES
₹1018 crore
For the FY19-20, Reliance Life Sciences (RLS) recorded a
KV SUBRAMANIAM revenue generation of Rs 1018 crore in the biopharma space
as compared to Rs 850 crore generated in the previous
President financial year, exhibiting a growth of 20 per cent.
Mumbai based RLS is part of the Promoter Group of
Reliance Industries Limited. RLS was established to develop business
opportunities in medical biotechnology with key initiatives in
biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical
research and molecular diagnostics.
The company currently has 6 products in the plasma proteins
portfolio that are manufactured at the company’s in-house cGMP
facilities. RLS has one pilot scale facility for plasma proteins in
Mumbai, one commercial scale facility for recombinant proteins
and monoclonal antibodies (mammalian and microbial cell culture
and fill finish for vials and syringes), one commercial scale facility for
plasma fractionation, and another commercial scale facility for plasma
proteins at Dhirubhai Ambani Life Sciences Centre, Navi Mumbai.
RLS has the distinction of being the first integrated manufacturer of
plasma proteins in South Asia.
On the biosimilars front, the company currently markets around
20 different biosimilars in India and overseas markets. These products
are manufactured in-house in two commercial scale facilities for
recombinant proteins and monoclonal antibodies (mammalian and
microbial cell culture and fill finish for vials and syringes). RLS has
launched five of the world’s first biosimilars, has the largest number
of biosimilars in the market in India, and the highest number of
biosimilars under development globally.
The Regenerative Medicine Group at RLS is involved in cord
blood banking and developing a wide range of novel research-led,
autologous and allogeneic cell therapies and tissue engineered
products, with the objective of bringing about an era of regenerative
medicine by unlocking the potential of human pluripotent stem
cells. Given the huge disease burden and the need for affordable
diagnostics and therapies in India, the Group aims to come up with
better and cost-effective ways to treat people with unmet medical
needs.
RLS is also developing novel therapeutics for treatment of cancer,
infectious diseases, inflammatory disorders, ocular disorders and
neurodegenerative disorders. The discovery programme is based on
siRNAs and monoclonal antibodies.
In addition, the company has established an institution dedicated
to providing postgraduate, doctoral research, professional and
continuing education programs in various domains of life sciences
and related technologies. Reliance Institute of Life Sciences (RILS) is
dedicated to specific areas of fundamental and applied research.

32 COVER STORY BIOSPECTRUM | FEBRUARY 2021 | WWW.BIOSPECTRUMINDIA.COM

09 BHARAT SERUMS
AND VACCINES LTD
REVENUE
BRINGING PATH
₹917 crore BREAKING PRODUCTS

SANJIV NAVANGUL Mumbai based biopharmaceutical company Bharat
Serums and Vaccines (BSV) recorded a revenue of Rs
Chief Executive Officer & 917 crore during the FY19-20 in the biopharma space,
Managing Director as compared to Rs 600 crore generated in the previous
year, marking a huge growth of 53 per cent.
The FY19-20 saw Advent International, one of the largest and
most experienced global private equity investors, signing a definitive
agreement to acquire a majority interest in BSV. With this transaction,
OrbiMed PE and Kotak PE, two private equity firms that previously
held minority positions in Bharat Serums, have fully exited their
investments in the company. The Daftary family, which founded BSV, is
retaining a meaningful equity stake in the business and has partnered
with Advent on the company’s next stage of growth.
The year 2019 also saw the entry of Sanjiv Navangul into the
company from Janssen India, taking charge of BSV as the Managing
Director (MD) and the Chief Executive Officer (CEO). Navangul has held
several leadership roles through his 30-year career such as Managing
Director for Janssen (Pharmaceutical Division of Johnson & Johnson)
in India and South Asia; Managing Director for MSD Pharmaceuticals,
Philippines; Commercial Director for MSD India and South Asia.
Founded in 1971, the company has a product portfolio of 25
brands which include plasma derivatives, monoclonal, fertility
hormones, antifungals, anesthetics, cardiovascular drugs and equine
immunoglobulin antitoxins. The products are sold through six specialty
areas namely gynecology; assisted reproductive technology; critical care;
emergency medicine; urology; neurology, nephrology and haematology.
BSV has an injectable plant located Ambernath, Maharashtra
housing 4 dedicated injectable lines targeting India and emerging
markets. Ambernath also stations a Biotech API & Injectable plant,
which is focused on biological and biotech products. The plant
has capabilities to manufacture commercial scale mammalian
cell cultured derived recombinant proteins and fill and finished
capabilities for liquid and lyophilized injectable products. The
company also has a horse farm in Maharashtra, with facilities for the
immunization of animals, plasmapheresis, plasma separation and on-
site testing under the supervision of qualified veterinary doctors.
The company has a comprehensive infrastructure for the
development of its products in its state of the art R&D facilities in
Thane, Maharashtra, with the capability to handle potent and cytotoxic
molecules.
BSV started its international business operations in early 2000.
The company’s products are registered in more than 45 countries
and its manufacturing facilities are accredited and certified by
various regulatory authorities from Asia, Latin America, Middle East,
Africa, etc.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 33

10 INTAS PHARMACEUTICALS LTD

REVENUE COMMITTED
TO INNOVATION
₹850 crore
Ahmedabad based Intas Pharmaceuticals recorded a
BINISH CHUDGAR revenue of Rs 850 crore in the biopharma space during the
FY19-20 exhibiting a growth of 20 per cent from the last
Managing Director fiscal’s revenue of Rs 708 crore.
During the FY19-20, the company took a revolutionary
step towards making therapy for chronic immune thrombocytopenia
(ITP) more accessible to patients by being the first to launch
Romiplostim in India under the name Romy. It is priced at Rs 2995
for a dose of 250 mcg, and the monthly cost of treatment for most
patients will be less than Rs 12,000, which is a huge relief to the chronic
ITP patients across the country.

Driven by a sustainable business model, Intas has been consistently
outperforming the market with a 14 per cent CAGR. Its 8 strategic
business units employ a multidivisional model, with 35+ marketing
divisions catering to various therapy areas for enhanced focus
towards brand development. On the foundation of this diversified
revenue base, Intas has gained a dominant presence in India with an
expanding market share and improving ranks across years.

50 per cent of Intas’ total domestic revenue is generated
from neurology, psychiatry and cardiovascular therapies. The
current emphasis is on central nervous system (CNS), nephrology,
cardiovascular, diabetology, gastroenterology, urology and pain
management therapies. While Intas enjoys leadership status in the
CNS segment, it has also been rapidly gaining equity in oncology,
rheumatology, ophthalmology, dermatology and infertility segments.

The company has an exhaustive coverage of key specialties like
neurologists, psychiatrists, cardiologists, diabetologists, consulting
physicians, urologists, nephrologists & oncologists with a substantial
prescriber base. The company is set to enhance its presence in the
market through its active progress in novel drug delivery system
(NDDS). Currently, Intas has launched 3 NDDS products in India using
patented technology.

Headed by a strong pool of 550+ scientists and researchers, R&D is
the key growth driver for Intas. Its constant quest for developing new
products and technology has led breakthrough innovations in a wide
spectrum of areas such as Oncology, Hormones & NDDS, apart from
other generic products. Till date, Intas has filed 50+ patents on novel
formulations, API polymorphs/processes & analytical methods to its
credit.

Intas’ Biologics Business Unit was launched in 2000 with a focus
on developing high-quality recombinant DNA protein (rDNA) products
and plasma-derived products. Its robust product portfolio consists of 13
commercialized products and a promising pipeline of 6 products.

34 CSTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

11 Hyderabad based vaccine manufacturer Indian
Immunologicals (IIL) recorded a revenue of Rs 820
INDIAN crore in FY19-20 in the biopharma space exhibiting a
IMMUNOLOGICALS LTD huge growth of 55 per cent from the last fiscal’s revenue of
Rs 538 crore. The company also generated a revenue of Rs 81
REVENUE crore in the other space including its contract manufacturing
business during FY19-20. The FY19-20 witnessed the company
₹820 crore investing Rs 75 crore in a new sterile filling facility (SFF) at its
manufacturing plant in Phase III of Genome Valley. The sterile
DR K ANAND KUMAR facility is equipped with hi-end filling equipment from the
world’s best manufacturers, in line with the requirements
Managing Director of the nature of work handled at the plant. The FY19-20 also
saw the Human Biologicals Institute, a division of IIL, taking a
12 significant step towards reducing the plastic burden on the
environment by launching an eco-friendly pack for its highly
PFIZER LTD successful anti rabies vaccine Abhayrab. The vaccine has
saved millions of lives from the fatal rabies disease since its
REVENUE launch two decades ago. With a total workforce of over 1400
employees, the company expects to record a turnover of Rs
₹519 crore 1100 crore for the FY 20-21 with the revenue from biopharma
targeted to be around Rs 929 crore.
S SRIDHAR
The Indian business of American multinational
Managing Director pharmaceutical corporation Pfizer recorded a revenue
generation of Rs 519 crore in the biopharma space
during FY19-20, showing a slight growth when compared
to the revenue figures of the FY18-19 which stood at Rs 511
crore. Headquartered in Mumbai, Pfizer India got started in
1950. The company has recently completed 70 years of its
operations in India. The key highlights for the company during
the FY19-20 were the launch of two innovative drugs Zavicefta
and Zinforo. Zavicefta, indicated for the management of
hospital-acquired pneumonia including ventilator associated
pneumonia (HAP/VAP), complicated intraabdominal infection
(cIAI) and complicated urinary infection (cUTI) in adults has
already recorded a business of over Rs 9 crore in the first
nine months of launch. On the other hand, Zinforo is a novel
cephalosporin indicated for treatment of adult patients with
community-acquired pneumonia. The vaccine business
focuses on Prevenar13, a pneumococcal conjugate vaccine
that is administered to children between 6 weeks to 17 years
and adults above 50 years of age. This vaccine provides
broad coverage against the most prevalent 13 serotypes
of streptococcus pneumoniae. Pfizer continues to enjoy a
leadership position in the pneumococcal vaccines market with
a share of 61 per cent. With its continuing preference among
pediatricians, Prevenar 13 is now the 13th ranked brand in the
Indian pharma industry.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 35

13 Ahmedabad based pharmaceutical company Zydus
Cadila recorded a revenue of Rs 513 crore during the
ZYDUS CADILA FY19-20 in the biopharma space, as compared to
HEALTHCARE LTD Rs 386 crore earned in the FY18-19, marking a significant
growth of 33 per cent. During the FY19-20, the company
REVENUE received an approval from Drug Controller General of India
(DCGI) for use of Saroglitazar Mg in the treatment of Type II
₹513 crore Diabetes Mellitus as an add on therapy with metformin. The
company also received marketing authorization for Twinrab
PANKAJ R PATEL or RabiMabs from DCGI. The novel biologic, which will be
marketed under the brand name Twinrab is indicated in
Chairman combination with rabies vaccine for rabies post-exposure
prophylaxis. Zydus also launched an affordable oral anti-
diabetic agent Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin
plus metformin) into the market in 2019. In addition, the
company also announced a partnership with SIFI, the
Italian leader in the development of therapeutic solutions
to treat ophthalmic disorders and for marketing innovative
intraocular lenses and surgical products developed in Italy
and licensed in India by SIFI. Towards the end of the FY19-
20, the company received an approval from the DCGI to
initiate phase I clinical trials for its Investigational New Drug
(IND) ZYBK2, a new chemical entity (NCE) intended to treat
Rheumatoid Arthritis (RA).

14 For the FY19-20, Mumbai based Lupin recorded a revenue
generation of Rs 478 crore in the biopharma space as
LUPIN LTD compared to Rs 400 crore generated in the previous
financial year, exhibiting a growth of 19 per cent. The FY19-20
REVENUE saw some major developments taking place at Lupin such
as the launch of Adhero, a new connected smart device for
₹478 crore metered-dose inhalers (MDI). This first-of-its-kind device is
designed to help patients with chronic respiratory diseases
VINITA D GUPTA track their MDI usage and facilitate improved adherence
to therapy. Lupin also announced entering into a definitive
Chief Executive Officer (CEO) agreement for the sale of its entire stake in its Japanese
subsidiary Kyowa Pharmaceutical Industry to Unison Capital
Partners IV, LPS and Unison Capital Partners IV (F). L.P., a
leading private equity fund in Japan with a strong track
record of success in the healthcare sector, for Rs 3702 crore.
The FY19-20 also saw Boehringer Ingelheim and Lupin
announcing a licensing, development and commercialization
agreement for Lupin’s MEK inhibitor compound (LNP3794) as
a potential targeted therapy for patients with difficult-to-treat
cancers. The partnership aims to develop Lupin’s lead MEK
inhibitor compound in combination with one of Boehringer
Ingelheim’s innovative KRAS inhibitors for patients with
gastrointestinal and lung cancers harboring a broad range of
oncogenic KRAS mutations.

36 CSTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

15 Mumbai based Macleods Pharmaceuticals recorded
a revenue of Rs 471 crore during the FY19-20 in the
MACLEODS biopharma space, showing a growth of 16 per cent
PHARMACEUTICALS from the previous financial year where the revenue count
PVT LTD was Rs 406 crore. With an experience of more than 2 decades,
Macleods is an established name in Indian pharmaceutical
REVENUE market. With its diversified product portfolio, Macleods
has gained leadership in various therapeutic segments.
₹471 crore The company’s product portfolio encompasses a wide
spectrum of therapeutic groups, ranging from anti-TB,
RAJENDRA AGARWAL asthma & COPD, anti-bacterial, NSAID, anti-arthritic, anti-
osteoporotic, gastroenterology, gynecology, diabetology and
Director CVS products. The R & D centre at Macleods is located in
Mumbai, which was setup in the year 2000, and is approved
16 by the Department of Scientific and Industrial Research,
Government of India. Besides that, the company also has a
ABBOTT INDIA LTD bioequivalence department established in 2005. Its clinical
and bio-analytical facilities and processes, are inspected by
REVENUE the Drugs Controller General of India (DCGI), US FDA, WHO
and MCC (South Africa). In addition, the manufacturing
₹395 crore facilities at Macleods are approved by international regulatory
agencies including USFDA, UK-MHRA, WHO-Geneva, MCC
ANIL JOSEPH South Africa, MOH - Saudi Arabia, MOH- UAE, MOH- Belarus,
MOH- Ukraine, INVIMA- Colombia, National Drugs Authority
Managing Director (NDA) Uganda, Food and Drugs Board, Kenya; Pharmacy
Board, Tanzania FDA, etc.

Arevenue generation of Rs 395 crore has been recorded
for the Indian arm of the American healthcare
company Abbott Laboratories in the biopharma
space for the FY19-20. This marks a 6 per cent growth for the
company in comparison to the revenue generation a year
before which was summed up at Rs 371 crore. During the
FY19-20, Abbott launched a new inactivated quadrivalent
vaccine for influenza, the first of its kind sub-unit vaccine
offering protection against four virus strains, in India. Another
major development that took place in the 2019 was the
launch of Abbott’s HD grid mapping catheter in India. It offers
physicians a unique grid configuration that captures this
critical information and enables the creation of high-density
maps of cardiac tissue to support optimal treatment for
patients. In addition, the FY19-20 also saw the exit of Jawed
Zia, who was serving at Abbott India as Vice President. Venu
Ambati, former Managing Director (MD) of Abbott India, has
stepped into this position. Few other initiatives led by Abbott
India during the FY19-20 include collaboration with Apollo
Hospitals for building India’s first cardiac registry, and a
partnership with the Indian Thyroid Society (ITS) & Federation
of Obstetric and Gynecological Societies of India (FOGSI) to
raise awareness on thyroid screening in pregnant women.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 37

17 For the FY18-19, Mumbai based Sun Pharma Industries
Ltd (SPIL) earned a revenue of Rs 193 crore in the
SUN PHARMA biopharma space as compared to Rs 172 crore
INDUSTRIES LTD generated in the previous financial year FY17-18, exhibiting a
profit of 12 per cent. The FY19-20 saw the company entering
REVENUE into a global licensing agreement with the Indian Institute
of Chemical Technology (IICT) in Hyderabad, for patents
₹193 crore related to certain compounds with potential therapeutic
activity across multiple indications in Sun Pharma’s
DILIP SHANGHVI specialty focus areas. A successful clinical development
of these potential compounds may enable Sun Pharma
Managing Director to commercialize pharmaceutical products for various
therapeutic indications over the long term. The company
also announced that one of its wholly owned subsidiaries
has granted an exclusive license to a subsidiary of China
Medical System Holdings to develop and commercialize
seven generic products in Mainland China. In addition,
Sun Pharma also entered into a licensing agreement
with AstraZeneca to introduce certain novel ready-to-use
(RTU) infusion oncology products in China. The agreement
is intended to bring cost effective and quality drugs to
patients in China. The company also announced an exclusive
licensing and supply agreements with Rockwell Medical in
the US, to commercialize Rockwell’s Triferic, a proprietary
iron replacement and haemoglobin maintenance drug, for
treating anaemia in hemodialysis patients in India.

18 Gurugram headquartered Eli Lilly and Company
(India), a wholly owned subsidiary of US based
ELI LILLY & COMPANY biopharmaceutical firm Eli Lilly and Company
(INDIA) PVT LTD recorded a revenue of Rs 183 crore in the biopharma space
during the FY19-20, growing by 14 per cent when compared
REVENUE to Rs 161 crore generated during FY18-19. Since its inception
in India in 1993, the company has been committed to
₹183 crore developing and marketing pharmaceutical products to
treat diabetes, gastric cancer, lung cancer, osteoporosis,
LUCA VISINI rheumatoid arthritis, men’s health and growth-hormone
deficiency. Lilly India affiliate also comprises operations in
Managing Director neighboring countries of Nepal, Bangladesh and Sri Lanka.
The company opened the Lilly Capability Centre India (LCCI)
in Bengaluru in January 2016. This centre allows Lilly to take
advantage of unique drug development capabilities found
in India. The company‘s work in India also encompasses
partnerships in MDR TB, Diabetes and Hypertension, as
well as community volunteering projects through Global
Day of Service, Connecting Hearts Abroad and a non-formal
education centre called STEP UP. At present, Lilly has one
of the richest mid-to-late stage pipelines in its history, with
7 molecules in regulatory review, 18 molecules in Phase III
clinical development, 13 molecules in Phase II testing and
24 molecules in Phase I. The company plans to bring these
innovative molecules to India depending on the market
needs over the next decade.

38 SCTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

19 Pune based Fresenius Kabi India, a 100 per cent
subsidiary of Fresenius Kabi AG Germany, recorded
FRESENIUS KABI a revenue count of Rs 182 crore in the biopharma
INDIA PVT LTD space during the FY19-20, exhibiting a growth of 26 per
cent as compared to the revenue generation in the FY18-19
REVENUE recorded at Rs 145 crore. Established in 1995, Fresenius Kabi
India deals in clinical nutrition; IV drugs which formulate
₹182 crore intravenously administered generic drugs such as oncology
drugs, anesthetics & analgesics, anti-infective & Critical
SANJAY GUPTA Care drugs. The portfolio also includes infusion therapy that
includes infusion solutions & colloids; and medical devices
Managing Director & Head MU-India that offer pumps, disposables, infusion management system,
products of collection & processing of blood components
& for therapeutic treatment of patients’ blood by apheresis
systems. In the field of biosimilars, the company develops
products with a focus on autoimmune diseases and oncology.
All these therapeutic areas are segmented in 9 different
business verticals functioning across various geographies. On
the global front, the company opened a new research and
development center for biosimilars in Switzerland during the
FY19-20. The R&D center, in which the healthcare company
has invested about €15 million, will strengthen Fresenius
Kabi’s capability to enable access to modern biosimilar
treatment options for patients worldwide.

20 The revenue generation for Pune based Emcure
Pharmaceuticals was Rs 173 crore during the FY19-
EMCURE 20 in the biopharma space in comparison to Rs 141
PHARMACEUTICALS LTD crore generated in the previous fiscal, showing a growth
of 22 per cent. The FY19-20 saw Vanta Bioscience’s step-
REVENUE down subsidiary Vayam Research Solutions entering
into a non-exclusive service agreement with Emcure for
₹173 crore providing services of bio-analytical and bio-equivalence to
the company for a period of three years from 2019 to 2022.
SATISH RAMANLAL MEHTA The company has a portfolio of 11 chiral molecules, eight of
which were launched for the first time in India. Emcure has 8
Chief Executive Officer & Managing Director brands covering various therapeutics areas related to blood,
oncology, HIV, gynecological, cardiac, anti-infectives. The R&D
activities are spread across its nine dedicated facilities located
in Pune, Ahmedabad and New Jersey. Out of the 9 R&D
centres, two are focused towards API research, five towards
formulations and two towards biotechnology research. The
R&D team is comprised of 500 highly qualified scientists
including post-doctorates, PhD holders and post-graduates.
On the other hand, Emcure’s manufacturing operations
are spread across 11 facilities globally. Its subsidiary Gennova
Biopharma, incorporated in the year 2001, is involved in
developing, manufacturing and marketing biotechnology
based products required for humans and veterinary purposes
in India and abroad.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 39

ABBOTT 21 PANACEA 22
HEALTHCARE PVT LTD BIOTEC LTD

Mumbai based Abbott Healthcare witnessed New Delhi based Panacea Biotec generated a
a revenue generation of Rs 157 crore in the revenue of Rs 140 crore in the biopharma space
biopharma space during the FY19-20, marking in the FY19-20 marking a decline of 36 per cent
a 22 per cent growth from the last year’s revenue when compared to the revenue during the FY18-
recorded at Rs 129 crore. Founded in 1997, the company 19 which was recorded at Rs 218 crore. The FY19-20
offers products in therapy areas such as respiratory, saw India Resurgence Fund, promoted by Piramal
gastro, dermal, nutritional, parenteral, anti-parasitic, Enterprises and Bain Capital Credit, along with its
gynecology, ophthalmology and otolaryngology, affiliates announcing an investment of up to Rs 992
oncology, cardiac, diabetes and hormones. Together, crore into Panacea Biotec. The company launched
Abbott India and Abbott Healthcare Pvt Ltd form the ViLACT for the treatment of uncontrolled Type 2
established pharmaceuticals business of Abbott in Diabetes Mellitus patients in 2019.
India.

HAFFKINE 23 BRILLIANT 24
BIO-PHARMACEUTICAL BIO PHARMA PVT LTD
CORPORATION LTD

The revenue generation for Mumbai based The revenue generation for Hyderabad based Brilliant
Haffkine Bio-Pharmaceutical Corporation, owned Bio Pharma (BBP) was Rs 125 crore in the biopharma
by the Maharashtra government, was recorded at during the FY19-20. The business declined by 4 per
Rs 126 crore in the biopharma space during the FY19- cent in comparison to the revenue generation of Rs 130
20, showing a growth of 48 per cent in comparison to crore during the previous fiscal. BBP has its presence in
the revenue count in FY18-19 at Rs 85 crore. Haffkine veterinary biologicals comprising of viral vaccines against
Ajintha Pharmaceuticals Ltd., a subsidiary of Haffkine foot-and-mouth disease (FMD) and rabies, bacterial vaccines
Bio-Pharma, develops a wide range of bacterial and against Haemorrhagic Septicaemia (HS), Blackquarter
viral vaccines, formulates pharmaceutical products, (BQ) & Enterotoxaemia (ET), and Animal Health Products
disinfectants, ointments, injectables, syrups and (AHPs) including Antibiotics and Antibacterials, Analgesics
mixtures. Haffkine introduced Scorpion Venom & Antipyretics, Dewormers, Ecto & Endo Parasiticides, Feed
Antiserum for the first time in India. Supplements, Galactogogues etc.

HESTER 25 LA RENON 26
BIOSCIENCES LTD HEALTHCARE PVT LTD

For the FY19-20, Ahmedabad based Hester Ahmedabad based La Renon Healthcare
Biosciences witnessed a revenue count of Rs recorded a revenue figure of Rs 92 crore during
120 crore in the biopharma space, exhibiting a FY19-20 in the biopharma space, exhibiting a
declining of 6 per cent in comparison to the revenue growth of 30 per cent when compared to Rs 71 crore
generated in the previous year at Rs 128 crore. The generated during previous financial year. The company
company has a product portfolio of over 50 vaccines majorly caters to segments such as nephrology, critical
and 35 health products distributed among four care, neurological disorders, urology, gastroenterology,
verticals: Poultry Vaccines, Animal Vaccines, Poultry respiratory and cardio metabolic. The company’s
Health and Animal Health. It is the second largest R&D centre has been accorded recognition by the
poultry vaccine manufacturer in India. The company Department of Scientific and Industrial Research
has a state-of-the-art manufacturing facility unit (DSIR), a department of the Ministry of Science and
in Mehsana, Gujarat, complying with stringent Technology under the Government of India.
international norms.

40 SCTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

MSD 27 DR. REDDY’S 28
PHARMACEUTICALS PVT LTD LABORATORIES LTD

Mumbai based MSD Pharmaceuticals recorded a Hyderabad based Indian multinational
revenue of Rs 85 crore in the biopharma space pharmaceutical company Dr. Reddy’s
during the FY19-20, exhibiting a decline in growth Laboratories earned a revenue of Rs 79 crore
when compared to its performance last year at Rs 96 crore. during the FY19-20 in the biopharma space, showing
Through its prescription medicines, vaccines, biologic a decline in its growth when compared to Rs 119 crore
therapies, and animal health products, MSD operates in earned in FY18-19. The company offers a portfolio
more than 140 countries. Since its existence in India, the of products and services including APIs, custom
company has moved quickly in laying the foundation pharmaceutical services, generics, biosimilars and
for a business that is differentiated by its focus through differentiated formulations. The major therapeutic
launching innovative products relevant to India. MSD in areas of focus are gastrointestinal, cardiovascular,
India also has presence in animal health via MSD Animal diabetology, oncology, pain management and
Health with its vaccines facility located in Pune. dermatology.

GLOBION 29 INDOVAX 30
INDIA PVT LTD PVT LTD

Secundarabad based Globion India, an arm Gurugram based poultry biotechnology company
of Suguna Holdings Private Limited (SHPL), Indovax recorded a revenue generation of Rs 70
generated a revenue figure of Rs 71 crore during crore in the biopharma space during the FY19-
the FY19-20 in the biopharma space, exhibiting a 20, exhibiting a growth of 36 per cent as compared
growth of 27 per cent in comparison to the revenue to the revenue generation of Rs 51 crore in the FY18-
generation of Rs 56 crore in the previous fiscal. 19. The company’s product portfolio contains 12 live
Globion produces a basket of poultry vaccines, live vaccines and 11 inactivated vaccines. Incorporated in
and inactivated, for breeders, layers and broilers. The 1986, the company produces over four billion doses
products are marketed under the brand GlobiVac. of vaccine annually that cater to the needs of the
domestic and international markets.

BHARAT IMMUNOLOGICALS 31 ZOETIS 32
AND BIOLOGICALS INDIA LIMITED
CORPORATION LTD

For the FY19-20, Bulandshahar based Bharat The Indian arm of the US based Zoetis clocked in
Immunologicals and Biologicals Corporation a revenue count of Rs 61 crore during the FY19-
(BIBC) witnessed a revenue generation of Rs 67 20. Zoetis discovers, develops, manufactures and
crore in the biopharma space, thereby exhibiting a commercializes medicines, vaccines and diagnostic
decline of 20 per cent in its growth from the revenue products, which are complemented by biodevices,
of Rs 84 crore recorded in the FY18-19. The company genetic tests and precision livestock farming. Zoetis
currently manufactures and produces a range of serves veterinarians, livestock producers and people
pharmaceuticals products such as Oral Polio Vaccines who raise and care for farm and companion animals in
(OPV Vaccine), Zinc Tablet & Diarrhea Management more than 100 countries. The company plans to step
Kit etc. BIBC was established as a Public Sector Unit in up efforts in the areas of bio-security, vaccination and
1989. automation in India in the coming years.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 41

MICRO 33 MANKIND 34
LABS LTD PHARMACEUTICALS LTD

For the FY19-20, Bengaluru based Micro Labs The revenue generation for New Delhi based
generated a revenue of Rs 60 crore in the Mankind Pharmaceuticals was recorded at Rs 58
biopharma space, showing a growth of 43 per cent crore in the biopharma space during the FY19-
when compared to Rs 42 crore generated in the FY18-19. 20, showing a growth of 12 per cent in comparison to
Micro’s product portfolio includes some of the topmost the revenue count in FY18-19 at Rs 52 crore. Mankind
brands in various specialties like cardiology, diabetology, has over 1000 products being marketed and more
anti-infectives, ophthalmology, pain, etc. Established than 200 products under development. The product
in 1973, Micro Labs is a multi-faceted healthcare portfolio caters to wide range of therapeutic areas such
organization with a proficient marketing team, state-of- as cardiology, respiratory, neurology, gastroenterology,
the-art manufacturing facilities and R&D centres that diabetology, dermatology, opthamology and
are at par with international standards. gynaecology.

RANBAXY 35 ZUVENTAS 36
LABORATORIES LTD HEALTHCARE LTD

Gurugram based Ranbaxy Laboratories generated Mumbai based Zuventas Healthcare witnessed a
a revenue of Rs 57 crore in biopharma space revenue generation of Rs 56 crore for the FY19-
during the FY19-20 exhibiting a slight growth 20 in the biopharma space, in line with the
in comparison to the revenue generation of Rs 56 revenue figure recorded during FY18-19 at Rs 57 crore.
crore in the previous fiscal. Incorporated in India in A joint venture of Emcure Pharmaceuticals, Zuventas
1961, it is an integrated, research based, international has its presence in the biotechnology (Enoxarin,
pharmaceutical company, producing a wide range Eporise, Peglast) and vaccines (Vac T, Zuvirab &
of quality, affordable generic medicines, trusted Zuvicella) segment. With more than 100 products in its
by healthcare professionals and patients across kitty, Zuventas has three manufacturing facilities.
geographies. Sun Pharma completed the acquisition of
Ranbaxy Laboratories in 2015.

CIPLA 37 PAVIOUR 38
LTD PHARMACEUTICALS PVT LTD

During the FY19-20, Mumbai based During FY19-20, New Delhi based Paviour
biopharmaceutical company Cipla generated a Pharmaceuticals witnessed a revenue count
revenue count of Rs 49 crore in the biopharma of Rs 44 crore in the biopharma space
space, growing by more than 57 per cent in showing a growth of 32 per cent in comparison to the
comparison to the revenue generated in the FY18-19 revenue generated in the FY18-19 at Rs 33 crore. The
that stood at Rs 32 crore. With 44 manufacturing sites company was incorporated in 1998 with the objective
around the world, Cipla produces more than 50 dosage of importing, marketing and distribution of various
forms and around 1,500 products using cutting-edge pharmaceutical specialty products, which are not
technology platforms to cater to 80 markets. Cipla indigenously produced.
had introduced Propranolol, the first beta blocker in
India way back in 1972. Since then, the company has
developed several products to treat many diseases.

42 SCTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

SAMARTH 39 SHREYA 40
LIFE SCIENCES PVT LTD LIFE SCIENCES PVT LTD

For the FY19-20, Mumbai based Samarth Life Mumbai based Shreya Life Sciences (SLS),
Sciences recorded a revenue count of Rs 43 the Indian arm of Shreya Group, witnessed
crore in the biopharma space, growing by 25 per a revenue generation of Rs 36 crore in the
cent when compared to the revenue generated in biopharma space during FY19-20, marking a growth
the FY18-19 at Rs 35 crore. Since its inception in 1963, of around 7 per cent in comparison to the revenue
the company has a built a product portfolio focused count of Rs 34 crore in the previous financial year. The
on therapeutics areas such as cardiology, oncology, company started its operations in India in 2001 by
neurology, pulmonology, antenatal medicines, IVF acquiring the pharma division of Rallis India Ltd., a TATA
medicines, to name a few. Group company. SLS operates through three Strategic
Business Units- Amadeus, AkuCare and BioLife.

RPG 41 WALLACE 42
LIFE SCIENCES LTD PHARMACEUTICALS PVT LTD

Mumbai based RPG Life Sciences recorded Goa based Wallace Pharmaceuticals Pvt Ltd
a revenue generation of Rs 30 crore in the generated a revenue of Rs 29 crore in the
biopharma space during the FY19-20, showing biopharma space during the FY19-20, exhibiting
a growth of 38 per cent when compared to the a growth of 22 per cent as compared to Rs 24 crore
revenue generated during the FY18-19 at Rs 22 crore. worth revenue generated in the FY18-19. The company
With manufacturing facilities located in Ankleshwar markets a basket of over 200 products focusing
and Navi Mumbai, the company is primarily focused on Antibiotics, Gastro-intestinal, Rheumatology,
on Pharmaceuticals, Fermentation and Biotechnology. Dermatology, Gynecology, Diabetology, ENT and
RPG Life Sciences, a part of RPG Enterprises, is Pediatrics. Wallace Pharma is a part of the Wallace
operating in the domestic and international markets Group, which also handles Indi Pharma and Goodwin
in the Branded Formulations, Global Generics and Biotechnology Inc.
Synthetic APIs space.

OZONE 43 ALKEM 44
PHARMACEUTICALS LTD LABORATORIES LTD

New Delhi based Ozone Pharmaceuticals Mumbai based Alkem Laboratories generated a
recorded a revenue generation of Rs 27 crore in revenue of Rs 25 crore in the biopharma space
the biopharma space in the FY19-20, showing during the FY19-20, showing a growth of 8 per
a decline in growth by 17 per cent when compared cent when compared to the revenue generation of Rs
to the revenue generated at Rs 33 crore during the 23 crore in the previous year. With 21 manufacturing
FY18-19. Ozone Pharmaceuticals is the formulation facilities at multiple locations in India and the US,
based drug manufacturing and marketing company, Alkem Labs gathers 32 per cent of its revenue via
with a focus across 14 therapy areas including pain offshore sales.
management, nutritional supplements, anti-infective,
cardiac, diabetes and hemostats, etc.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com COVER STORY 43

JUGGAT 45 FERRING 46
PHARMA LTD PHARMACEUTICALS PVT LTD

During the FY19-20, Mysuru based Juggat The Indian subsidiary of Swiss multinational
Pharma generated a revenue count of Rs 24 company Ferring Pharmaceuticals generated a
crore in the biopharma space, growing slightly revenue figure of Rs 23 crore in the biopharma
in comparison to the revenue generated in the space during FY19-20, growing at 19 per cent in
FY18-19 at Rs 23 crore. A part of Jagdale Industries, comparison to Rs 19 crore generated in the FY18-
Juggat Pharma manufactures tablets, liquid orals, 19. Ferring deals with reproductive medicine and
capsules, granules and small volume parenterals. With women’s health with strong presence in areas within
around 40 products in its portfolio, the company has gastroenterology and urology.
distribution network spans all over India.

BOEHRINGER INGELHEIM 46 ASTRAZENECA 47
INDIA PVT LTD PHARMA INDIA LTD

The Indian arm of Germany based Boehringer For the Indian arm of the British pharmaceutical
Ingelheim recorded a revenue generation of Rs firm AstraZeneca, the revenue generation was
23 crore in the biopharma space in the FY19-20, Rs 21 crore during the FY19-20 in the biopharma
showing a growth of 24 per cent when compared space in line with the revenue generation of Rs 21 crore
to the revenue generated during the FY18-19 at in the previous year. During the FY19-20, AstraZeneca
Rs 18 crore. Mumbai based Boehringer Ingelheim India announced the launch of Qtern (Dapagliflozin
India operates through its business areas of human 10mg + Saxagliptin 5mg film Coated Tablets) for
pharmaceuticals, animal health and clinical operations. treatment of type 2 diabetes mellitus (T2DM). Qtern is
During the FY19-20, the company announced a indicated as an adjunct to diet and exercise to improve
partnership with Lupin for developing novel oncology glycaemic control in adults with T2DM.
drugs.

JAGSONPAL 48 CORONA REMEDIES 48
PHARMACEUTICALS LTD PVT LTD

New Delhi based Jagsonpal Pharmaceuticals The revenue count in the FY19-20 for Ahmedabad
recorded a revenue generation of Rs 19 crore in based Corona Remedies was Rs 19 crore in the
the biopharma space in the FY19-20, showing a biopharma space, marking a decline of 5 per cent
decline of 5 per cent when compared to the revenue when compared to the revenue generated during the
generated during the FY18-19 at Rs 20 crore. Founded FY18-19 at Rs 20 crore. For Corona, cardio metabolic
in 1964, the company specializes in developing and and nutraceuticals segments are the focus areas,
manufacturing bulk drugs and pharmaceutical while it has a significant presence in the gynecology,
formulations. Besides India, the company’s operations infertility and neuropathy segments.
span Russia, Brazil, USA, Ukraine, Sri Lanka, Cameroon,
Thailand, Argentina, Germany, Switzerland, Korea,
Egypt and Vietnam.

44 SCTOAVRETRUSPTSORY BIOSPBEIOCSTPREUCMTRU|M FE|BRFUEABRRYU2A0R2Y120|21 W|WWw.BwIOwS.bPioEsCpTeRcUtrMumINinDdIAia..CcOomM

NEON 48 CLARIS 49
LABORATORIES LTD LIFESCIENCES LTD

The revenue count in the FY19-2 for Mumbai The revenue generation for Ahmedabad based
based Neon Laboratories was Rs 19 crore in the Claris Lifesciences, the Holding Company of
biopharma space, marking a growth of 5 per cent Claris Injectables Limited, has been continuously
when compared to the revenue generated during the declining since the FY16-17. However, the revenue had
FY18-19 at Rs 18 crore. Since 1982, the company has picked up slightly last year owing to the fact that Claris
been constantly expanding its business by developing, Injectables was sold to Baxter International in July 2017.
licensing, manufacturing and marketing. The group is But during the FY19-20, the company experienced a
presently having 3 manufacturing facilities confirming dip in sales with the revenue figure standing at Rs 18
to Good Manufacturing Practice as prescribed by crore in the biopharma space as compared to Rs 25
World Health Organization. crore generated in the previous year.

MERCURY 49 CADILA 50
HEALTHCARE PVT LTD PHARMACEUTICALS LTD

Mumbai based Mercury Healthcare recorded Ahmedabad based Cadila Pharmaceuticals
a revenue generation of Rs 18 crore in the generated a revenue of Rs 17 crore in the
biopharma space in the FY19-20, showing a biopharma space, exhibiting a dip of 16 per cent
growth of 8 per cent when compared to the revenue as compared to Rs 21 crore worth revenue generated
generated during the FY18-19 at Rs 17 crore. The in the FY17-18. The company’s focus therapy areas
company manufactures stable and therapeutically include gastroenterology, cardiology, cardiovascular,
effective formulations in independent manufacturing gynaecology and diabetology. The manufacturing
facilities across India. facilities at Cadila Pharma are approved by stringent
International bodies like WHO-GMP, UK-MHRA,
USFDA-API, TGA-Australia, and AIFA-Italy.

OAKNET 50 RAPTAKOS, BRETT 50
HEALTHCARE PVT LTD & CO. LTD

For Bengaluru based Oaknet Healthcare, the The revenue generated in the FY19-20 for Mumbai
revenue generation was Rs 17 crore during the based Raptakos, Brett & Co. was at Rs 17 crore in
FY19-20 in the biopharma space, exhibiting a the biopharma space, marking a growth of 7 per
growth of 7 per cent when compared to revenue cent when compared to the revenue generated during
generation of Rs 16 crore during the FY18-19. With the FY18-19 at Rs 16 crore. The company specializes
heritage brands like Cosvate & Flucos in Dermatology in pharmaceuticals and nutraceuticals based
and Jectocos & Ferose in Gynaecology, the major products. The company’s pharmaceutical products
focus therapy areas for the company are Cardiology, cover several therapeutic areas such as haematinics,
Diabetology, Orthopedics. Oaknet is an entrepreneurial gastrointestinals, digestive enzymes, to name a few.
venture set up in 2015 by former Lupin executive RS
Raghav.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com PEOPLE NEWS 45

Dr TS Kler steps in as Chairman of Fortis Heart Institute

Fortis Healthcare has roped in an and heart failure, and strengthen Fortis’s
eminent interventional cardiologist and cardiology patient care in Gurugram
electrophysiologist with global repute and Vasant Kunj. Dr Kler was the first
to lead its Heart & Vascular Institute. doctor in India to implant an Implantable
Honoured with Padma Bhushan, Dr Cardioverter Defibrillator, Cardiac
TS Kler brings with him 30 years of Resynchronisation Therapy (CRT) and
rich experience including many clinical Cardiac Resynchronisation Therapy
landmarks and firsts in his field. He will Defibrillator (CRT-D) (Heart Failure Device).
lead the Fortis Heart & Vascular Institute He performed the first His Bundle
from two of its hospitals in Delhi Pacing (Conduction System
NCR; i.e. Fortis Memorial Pacing) in India in 2015.
Research Institute (FMRI) He was instrumental in
at Gurugram and Fortis Flt starting Radio Frequency
Lt Rajan Dhall Hospital at Ablation and cardiac device
Vasant Kunj, New Delhi. implantation programme
Dr Kler & his team will in many cardiac centres in
strengthen the cardiology South Asia. Dr Kler was
and vascular programme the founding president
with special focus on of IHRS (Indian Heart
electrophysiology Rhythm Society).

Paras Healthcare Cytecare Cancer
appoints Dr Teotia
as Group Head of HR Hospitals brings

Paras Healthcare has announced the appointment of Dr Swati Bhat
Dr Shashank Teotia as the Group of Head of Human
Resources (HR). With his vast experience of 17 years on board
primarily in human resources, Dr Teotia will aim to
maximise the value of the organisation’s HR department Cytecare Cancer Hospitals has announced
and bring in new ideas and innovations to ensure efficient the appointment of Dr Swati Bhat as
business operation. Prior to this role, Dr Teotia worked Consultant – Pain and Palliative Care,
with prestigious organisations like LEAD School, Max Interventional Spine
Life Insurance, IBIBO & Mother Dairy to name a few. He Specialist. Dr Swati
is a trained MD in
has been instrumental in leading talent anaesthesiology, and
and organisation strategy across super specialises
various organisations helping them in chronic pain
to deliver their vision. His expertise management. She
lies in organisational transformation specialises in minimally
& restructuring, culture building, invasive advanced
organisational development, automation spine interventions
& HRIS. He has created strong like - Vertebroplasty,
synergies between performance Biacuplasty, and
management processes and Intrathecal drug
employee development delivery systems
platforms, ensuring that and Radiofrequency
the organisation has a neuroplasty
competent, readily available procedures. She will
internal talent pool to meet also lead the Palliative Care Fellowship
business challenges. programme that was launched this year
under the aegis of Rajiv Gandhi University
of Health Sciences (RGUHS) at Cytecare.

46 SPONSORED CONTENT BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com
ADVERTORIAL

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com SPONSORED CONTENT 47

48 PEOPLE NEWS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

Pink Tech Design GAVI nominates Dr Harsh
ropes in Dr S Vardhan as India representative
Pandurangan
for AI expertise Dr Harsh Vardhan, Union Minister, Health and Family Welfare
has been nominated by the Global Alliance for Vaccines and
Pink Tech Design, based in Immunisation (GAVI) as a member of the GAVI Board. He will
New Delhi, has announced the be representing the South-East Area Regional Office (SEARO)/
appointment of Dr Sundaramurthy Western Pacific Regional Office (WPRO) constituency on the GAVI
Pandurangan as head of Artificial Board from January 1, 2021 until December 31, 2023. The seat was
Intelligence (AI) and Data previously held by MyintHtwe of Myanmar. A major pioneering
Sciences. He will join the board initiative of Dr Harsh Vardhan
that has industry experts like Dr has been his act of implementing
Kanav Kahol, Former Professor, World Health Organisation (WHO)
Arizona State University and Mayo Essential Drug Programme, which
Clinic US, Dr Priyamvada Tripathi, revolutionised governments’ attitudes
CEO, Pink Tech Design, making on public healthcare. Under the
it a powerful, diverse and truly concept, maximum budgetary outlay
global combination. Pink Tech was apportioned to those drugs most
Design Pvt Ltd is working towards needed by the people. His life-long
bringing AI and Data Sciences into commitment to polio eradication
medical practice in India. As the continues notwithstanding his being
head of AI and Data Sciences, Dr in power or not. To this end, he also
Pandurangan comes with hands- served the South-East Asia office of WHO as an Advisor. He is
on experience of more than 13 the first Indian to have been nominated to the prestigious WHO
years, working with some of the body, the Strategic Advisory Group of Experts (SAGE), in which
most renowned organisations in capacity he counseled the international body on developing policies
India and the world. He will play on vaccines and biologicals. Apart from this, he has served on the
an integral role in developing Global Technical Consultative Group and the Technical Consultative
and strengthening our AI Group of the South East Asia region for polio eradication. This is the
application development team. Dr highest body of WHO dedicated to the elimination of polio.
Pandurangan is a mathematician
by training who earned his PhD Slayback Pharma names
from the Indian Institute of Dr Sumitra Pillai as Vice
Technology Roorkee (IIT Roorkee). President and R&D Head
Prior to his current position,
he has served as a professor at US based Slayback Pharma has
the Alliance University, made a announced the appointment of Dr
unique contribution to teaching Sumitra Pillai as Vice President and the
data science (machine learning new Head of R&D. Dr Sumitra will be
algorithms), management based out of Slayback’s Hyderabad office.
science (operations research) and Dr Sumitra is a highly accomplished
biological science (human anatomy scientist with a stellar track record in
and physiology for engineers). the development and scale-up of highly
complex, differentiated and difficult-
to-make generics. Prior to joining
Slayback, she was the Vice President
of Research and Development at Dr.
Reddy’s Laboratories where she was
instrumental in successful development
of numerous complex injectables and
ophthalmic products.

BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com R&D 49

THSTI offers novel PoC test for malaria detection

A recent collaborative study to detect infection in populations
between Faridabad based from different regions and those
Translational Health Science and affected by different strains of
Technology Institute (THSTI) the parasite. It was found to
and University of Turku, Finland detect even at low levels of 0.2-2
has revealed the development parasites/microlitre, depending
of a highly sensitive and robust on the strain. This is a 50-to
point-of-care (PoC) test that 250-fold improvement over
can detect malaria infection. conventional rapid diagnostic
The test was validated by tests in use currently. It is also
running samples containing found to be stable even at 40
different strains of Plasmodium degrees C for at least 5 months,
falciparum from different thus making it quite suitable
geographical areas. The results for the tropical regions, most
indicate that the test can be used affected by this parasite.

BARC develops CSIR reveals anti-viral
benefits of chlorhexidine
indigenous Ruthenium mouthwash

106 plaque to A preliminary laboratory based research conducted
by researchers at Panjab University in collaboration
treat eye cancer with CSIR-Institute of Microbial Technology
(IMTECH) has revealed that one of the most
Dr Jitendra Singh, Union Minister of State routinely used mouth rinses, Chlorhexidine, has
(Independent Charge) Development of North proven to be effective against SARS-CoV-2. The
Eastern Region (DoNER), MoS PMO, Personnel, study, titled ‘Chlorhexidine: An effective anti-
Public Grievances, Pensions, Atomic Energy and COVID mouth rinse’ was supported by Dr. Reddy’s
Space has lauded the Bhabha Atomic Research Laboratories and Design Innovation Centre
Centre (BARC) in Mumbai for developing eye in Panjab
cancer therapy in the form of the first indigenous University.
Studies have
Ruthenium 106 plaque shown that
for treatment of ocular SARS-CoV-2
tumours. The handling of virus colonises
plaque is very convenient in the oral and
for the surgeon and it nasal cavities.
has been acknowledged Mouth rinses
to be at par with the can be an
international standards. All effective way
India Institute of Medical to reduce the colonisation and possibly reduce
Sciences (AIIMS), New the transmission of infection. The public at large
Delhi agreed to use the has become very conscious about oral hygiene in
plaque developed by BARC these COVID times so as to prevent SARS-CoV-2
for eye cancer treatment infection. Chlorhexidine is a gold standard mouth
and it was in September 2020 that it was used for rinse due to its broad spectrum bactericidal
the first time for the treatment of a patient with and virucidal properties. This study was aimed
choroidal hemangioma and the results proved to be at providing an insight into the effectiveness of
satisfactory. So far the BARC plaques made in India Chlorhexidine 0.2 per cent against SARS-CoV-2,
through the Department of Atomic Energy have through an analysis in a laboratory.
been used for seven cases for ocular cancer, out of
which two were retinoblastoma, two were choroidal
melanoma, two ocular surface squamous neoplasia
(OSSN) and one case of choroidal hemangioma.

50 SUPPLIERS NEWS BIOSPECTRUM | FEBRUARY 2021 | www.biospectrumindia.com

HiMedia Shadowfax, SpiceXpress to
arrange speedy transportation
gets multiple of COVID-19 vaccines

nods for Shadowfax, an integrated pickups and last mile deliveries
3PL services provider based through a verified network of
COVID-19 in Bengaluru, has announced delivery partners operating across
a strategic partnership with 500+ cities covering more than
products SpiceXpress, the largest cargo 7000 pin codes in India.
Airline in India to provide a
HiGenoMB, the seamless solution in transporting
molecular biology the temperature sensitive COVID-19
division of Mumbai vaccine. Shadowfax plans to deploy
based firm HiMedia a fleet of over 250 refrigerated
Laboratories has received vehicles, which will provide a
the CE/IVD approval and speedy and reliable transportation
a nod from the Indian solution for vaccine delivery
Council of Medical through a sustainable cold chain
Research (ICMR) for network. For the COVID-19 vaccine
its COVID-19 range movement, Shadowfax will provide
of products. Hi-PCR logistics support to cover first mile
Coronavirus (COVID-19)
Multiplex Probe PCR Kit Godrej ramps up medical
is capable of detecting 4 refrigerator production
different genes- N gene,
E gene, RdRp gene and To cater to the urgent demand for COVID-19 vaccine storage in India,
RPPH1 (Endogenous Godrej has a range of vaccine refrigerators, which operate in the precise
Internal Control) in the temperature band of 2-8°C and now, also offers advanced medical freezers
same assay. On the other with cooling upto -20°C. These temperature ranges are completely suited
hand, HiPurA Viral RNA for the multiple COVID-19 vaccines being evaluated by India. Powered
Purification Kit has been
the front runner amongst by patented Sure Chill Technology, Godrej
the COVID products Medical Refrigerators help maintain the
for HiGenoMB. HiPurA optimum temperature range of 2 to 8°C - a
Viral RNA Purification necessity for vaccine preservation, despite
Kit – Magnetic Bead intermittent power outages. In the
Based product was event of power outages, this refrigerator
approved from ICMR- retains its temperature for as long as
approved site National 8-12 days even at ambient temperatures
Institute of Virology of 43°C. The brand has received multiple
in Pune along with its orders valued close to Rs 150 crore
use with HiMedia’s from the central government, various
Automated DNA/RNA state governments and international aid
Instrument- InstaNX bodies as well, solely for the purpose
Mag96. HiMedia Labs of COVID-19 vaccine storage. It is also
has also successfully receiving enquiries now from Public
launched the InstaNX Sector Undertakings, who are joining the
Mag Series of Automated immunisation effort. Godrej Appliances
DNA/RNA Extraction has already ramped up medical
Platforms viz InstaNX refrigerator production capacity from
Mag32 capable of 10,000 units per annum to 35,000 units
processing 32 samples per annum, to meet the growing demand.
& InstaNX Mag96, the
high throughput version
capable of processing 96
samples.